<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223810</article-id>
    <article-id pub-id-type="pmid">38686808</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae326</article-id>
    <article-id pub-id-type="publisher-id">gkae326</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemoDOTS: a web server to design chemistry-driven focused libraries</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1906-7128</contrib-id>
        <name>
          <surname>Hoffer</surname>
          <given-names>Laurent</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2806-8675</contrib-id>
        <name>
          <surname>Charifi-Hoareau</surname>
          <given-names>Guillaume</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1084-6312</contrib-id>
        <name>
          <surname>Barelier</surname>
          <given-names>Sarah</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5935-5058</contrib-id>
        <name>
          <surname>Betzi</surname>
          <given-names>Stéphane</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8645-2785</contrib-id>
        <name>
          <surname>Miller</surname>
          <given-names>Thomas</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9877-6058</contrib-id>
        <name>
          <surname>Morelli</surname>
          <given-names>Xavier</given-names>
        </name>
        <!--xavier.morelli@inserm.fr-->
        <xref rid="COR2" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5580-0588</contrib-id>
        <name>
          <surname>Roche</surname>
          <given-names>Philippe</given-names>
        </name>
        <!--philippe.roche@inserm.fr-->
        <xref rid="COR1" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +33 486 977 335; Fax: +33 486 977 499; Email: <email>philippe.roche@inserm.fr</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dr Xavier Morelli. Email: <email>xavier.morelli@inserm.fr</email></corresp>
      <fn id="FN1">
        <p>The first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-30">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W461</fpage>
    <lpage>W468</lpage>
    <history>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>11</day>
        <month>3</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae326.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>In drug discovery, the successful optimization of an initial hit compound into a lead molecule requires multiple cycles of chemical modification. Consequently, there is a need to efficiently generate synthesizable chemical libraries to navigate the chemical space surrounding the primary hit. To address this need, we introduce ChemoDOTS, an easy-to-use web server for hit-to-lead chemical optimization freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. With this tool, users enter an activated form of the initial hit molecule then choose from automatically detected reactive functions. The server proposes compatible chemical transformations via an ensemble of encoded chemical reactions widely used in the pharmaceutical industry during hit-to-lead optimization. After selection of the desired reactions, all compatible chemical building blocks are automatically coupled to the initial hit to generate a raw chemical library. Post-processing filters can be applied to extract a subset of compounds with specific physicochemical properties. Finally, explicit stereoisomers and tautomers are computed, and a 3D conformer is generated for each molecule. The resulting virtual library is compatible with most docking software for virtual screening campaigns. ChemoDOTS rapidly generates synthetically feasible, hit-focused, large, diverse chemical libraries with finely-tuned physicochemical properties via a user-friendly interface providing a powerful resource for researchers engaged in hit-to-lead optimization.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae326figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Agence Nationale de la Recherche</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001665</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ANR-20-CE18-0025</award-id>
        <award-id>ANR-21-CE18-0056</award-id>
        <award-id>ANR-22-CE18-0023</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R37 CA218259</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC2">
    <title>Introduction</title>
    <p>While the identification and validation of hit compounds is a nontrivial first step in the drug discovery process, these compounds normally require subsequent optimization to improve their efficacy, selectivity, and drug-like properties to become chemical probes or therapeutic candidates. During this optimization phase, vast chemical spaces are explored to find analogs or derivatives of the initial hit compounds with improved potency, selectivity, and better pharmacological properties. However, this hit-to-lead (H2L) optimization phase is usually a major bottleneck in drug discovery campaigns (<xref rid="B1" ref-type="bibr">1</xref>). Computational methods are increasingly being integrated into the H2L optimization process to aid in predicting compound properties, optimizing chemical structures, and prioritizing analogs for synthesis (<xref rid="B1" ref-type="bibr">1–5</xref>). One widely established approach to optimize validated hits is known as ‘growing’. This involves expanding chemical structures to introduce new interactions with the target, in order to improve potency and selectivity (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). However, a notable drawback emerges because of this strategy where the molecular weight of the compounds increases, outpacing gains in target affinity or activity, and leading to a phenomenon known as ‘molecular obesity’ (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). Therefore, it is crucial to initiate the H2L optimization phase with so-called ‘ligand-efficient’ molecules exhibiting a low molecular weight and high activity or potency. Such compounds can be obtained through the deconstruction or structural simplification of larger validated hit molecules (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>) or starting with lower molecular weight compounds. Therefore, fragment-based drug discovery (FBDD) appears as one of the most relevant approaches to identify initial hits (<xref rid="B12" ref-type="bibr">12–16</xref>). Fragments are low molecular weight chemical compounds defined by the rule of three (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). One of the key advantages of fragment libraries, compared to standard chemical libraries used in high-throughput screenings, lies in the fact that a small number of fragments can effectively represent a vast chemical space (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In addition, fragments also exhibit high hit rates compared to larger compounds. Because of the small size and low complexity of fragment molecules, FBDD is often combined with structure-based approaches to optimize the initial hits and increase their efficiency and specificity (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). One important aspect of the H2L optimization strategy is considering the synthetic feasibility of the designed compounds. Indeed, each iteration of the growing strategy, aimed at exploring the chemical space around the initial hit, involves synthesizing the designed analogs and testing them experimentally. Achieving this is typically performed through two main strategies. The synthetic feasibility can be estimated using machine learning approaches and expressed through a retrosynthetic score (<xref rid="B23" ref-type="bibr">23</xref>). Alternatively, carefully selected chemical reactions can be employed to virtually design potentially optimized compounds, as demonstrated by the curated collection proposed by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). In this collection, 58 medicinal chemistry-relevant chemical reactions commonly used during the H2L optimization stage in the pharmaceutical industry have been encoded in the machine-readable SMARTS format. These reactions have been implemented in several approaches including DOGS (<xref rid="B25" ref-type="bibr">25</xref>), CROSS (<xref rid="B26" ref-type="bibr">26</xref>), PINGUI/SCUBIDOO (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>), AutoCouple (<xref rid="B29" ref-type="bibr">29</xref>), NAOMINEXT (<xref rid="B30" ref-type="bibr">30</xref>), CHIPMUNK (<xref rid="B31" ref-type="bibr">31</xref>), SwissDrugDesign (<xref rid="B32" ref-type="bibr">32</xref>), AutoGrow4 (<xref rid="B33" ref-type="bibr">33</xref>), OpenChemLib (<xref rid="B34" ref-type="bibr">34</xref>) and eXplore (<xref rid="B35" ref-type="bibr">35</xref>). We also implemented this collection of reactions into our integrated drug design strategy called diversity-oriented target-focused synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). The DOTS approach combines the design of focused chemical libraries and virtual sampling to prioritize the best potential optimizations. Briefly, after hit identification and characterization of its binding mode using structural biophysics method, such as X-ray crystallography, a virtual library is generated. This is achieved by combining an activated core analog of a hit fragment, with a collection of functionalized building blocks (BBs) using the chemical reactions previously defined by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Post-processing stages are then applied to extract a diverse subset of representative compounds that possess reasonable physicochemical properties and are devoid of any undesirable chemical functions. The final library undergoes virtual screening with the S4MPLE tool (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>) to identify the best putative optimizations, aiming to create additional favorable contacts while maintaining the original binding mode. The DOTS approach has been successfully applied to various targets including the zika virus NS5 protein (<xref rid="B39" ref-type="bibr">39</xref>), syntenin PDZ domain protein (<xref rid="B40" ref-type="bibr">40–42</xref>), bromodomain-containing protein 4, BRD4 (<xref rid="B43" ref-type="bibr">43</xref>) and, more recently, a nucleotide kinase, dCK (<xref rid="B44" ref-type="bibr">44</xref>).</p>
    <p>As demonstrated above, the ensemble of chemical reactions defined by Hartenfeller <italic toggle="yes">et al.</italic> is widely used in the chemoinformatics community. However, there is currently no easy-to-use freely accessible web server able to efficiently generate large ready-to-dock virtual libraries using these chemical reactions. In response to this gap, we introduce the ChemoDOTS web server designed to facilitate the generation of focused virtual libraries starting from a user-defined activated fragment. The user first proceeds by uploading or drawing a hit fragment in a sketcher. The web server then automatically identifies the chemical functions that permit the virtual coupling of BBs on the starting molecule. The user then selects one of the identified chemical functions and chooses from a list of compatible chemical reactions. Subsequently, a raw chemical library corresponding to the given reactions and compatible BBs is generated. At this stage, the user is given the option to apply a detailed set of post-processing filters to extract drug-like compounds with specific physicochemical properties. The final stage involves the computation of explicit stereoisomers and tautomers and the generation of a 3D conformer for each compound. A resulting virtual library compatible with most docking software is supplied as mol2 files with atom types and partial charges. The web server is freely accessible to all users, including commercial users, at the following address <ext-link xlink:href="http://chemodots.marseille.inserm.fr/" ext-link-type="uri">http://chemodots.marseille.inserm.fr/</ext-link>.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC3">
    <title>Materials and methods</title>
    <sec id="SEC3-1">
      <title>Web server architecture</title>
      <p>The web server is composed of two parts: the frontend, which handles user interactions, and the backend, which performs the computations. The frontend is a single-page application (SPA) designed with the React framework and embedding the MarvinJS sketcher version 22.11.1 from Chemaxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The backend server is written in Rust to speed up response time. It runs under a virtualized (KVM) Linux instance with a 4 cores/8 hyperthreads Intel CPU, 32 GB of RAM and 90 GB of storage. It makes use of a PostgreSQL database to store all the internal data (e.g. chemical functions, encoded chemical reactions, building blocks) and user-submitted data.</p>
      <p>The raw compound references were stored separately from the building blocks to facilitate the treatment of duplicate molecules within or across providers while maintaining traceability. Chemical reactions, building blocks, and starting fragments were stored in their source/human readable format (SMARTS for reactions, SMILES for building blocks and fragments) to allow extensibility and direct compatibility with external tools. Additionally, they were stored in the RDkit pickle binary format which does not require sanitization and reduces loading time. Each operation was heavily parallelized using a thread pool across all available CPU cores to guarantee maximum performance. This was achieved through Rust's fearless concurrency mechanisms and the Rayon crate for parallel iterators. Database indexes were carefully defined to avoid computational bottlenecks without increasing the database size and reindexing workload for the database management system. To prevent unnecessary calculations, the list of building blocks available for each reaction was precomputed and stored within the database. The combined use of these optimizations allows fast chemical library generation producing at least 50 000 compounds per minute per reaction.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Generation of raw chemical library</title>
      <p>All the chemoinformatics operations are performed using the RDKit framework version 2023.09.5 (<ext-link xlink:href="https://www.rdkit.org/" ext-link-type="uri">https://www.rdkit.org/</ext-link>) unless otherwise stated.</p>
      <sec id="SEC3-2-1">
        <title>Preparation of building blocks</title>
        <p>The list of 626 026 commercially available building blocks as of 2024-02 was retrieved from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) as an SDF file. Then, a standardization pipeline was applied to discard undesirable compounds. First, for each compound, the largest organic fragment was selected discarding salts. The compounds containing only organic atoms (H, C, N, O, P, S), halogens (F, Cl, Br, I) or other atoms relevant in medicinal chemistry (B, Sn) were kept while explicit isotopes were filtered out. A series of filters were then applied to only retrieve BBs with &lt;2 unspecified stereocenters, less than 17 rotatable bonds to limit flexibility, less than 4 rings and between 5 and 24 heavy atoms to restrict the molecules size to an acceptable range. Finally, the compound charges were neutralized. The standardized building blocks were converted into canonical SMILES allowing duplicates to be identified and grouped together with the same internal reference. The resulting chemical structures were serialized using the RDKit pickle format for faster loading from database storage. In the end, 501 542 unique building blocks from MolPort were kept. The same pipeline was applied for the 1 254 866 commercially available building blocks as of 2024-02-05 from the Enamine comprehensive catalog (<ext-link xlink:href="https://enamine.net/building-blocks/building-blocks-catalog" ext-link-type="uri">https://enamine.net/building-blocks/building-blocks-catalog</ext-link>), resulting in the selection of 988 112 unique building blocks.</p>
      </sec>
      <sec id="SEC3-2-2">
        <title>Detection of reactive functions</title>
        <p>Reactive functions are detected by matching each building block against the chemical reactions. A substructure match is performed between an expected reactant template and a building block so that all the reacting building blocks for a given reaction are pre-identified and stored inside the database.</p>
      </sec>
      <sec id="SEC3-2-3">
        <title>List of chemical reactions</title>
        <p>The list of 58 SMART-encoded reactions was taken from the publication of Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Several in-house reactions (numbered 61–70) used in internal projects have been added to overcome some exceptions in the original list of reactions. The complete list of reactions and their corresponding SMARTS are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>.</p>
      </sec>
      <sec id="SEC3-2-4">
        <title>Detection of compatible chemical reactions</title>
        <p>To identify reactions compatible with a selected chemical function on a provided fragment, the reactant templates from the reaction SMARTS are matched against the fragment to identify the reacting atoms. Only reactions for which one template shares at least one common atom with the function are kept.</p>
      </sec>
      <sec id="SEC3-2-5">
        <title>Generation of raw chemical library</title>
        <p>All fragment atoms not involved in the reaction are masked to prevent reactions with unwanted functions and to speed up the process. Next, the reaction products are generated. Building blocks leading to more than one distinct product are discarded. The products are then grouped by canonical SMILES to identify duplicates (if any) and the 2D coordinates are generated. At this stage, a set of molecular descriptors are computed. These descriptors are the fraction of sp<sup>3</sup> carbons over the total carbon count (Fsp<sup>3</sup>), the number of hydrogen bond donors (HBD), the number of hydrogen bond acceptors (HBA), the logarithm of the predicted partition coefficient between octanol and water (cLogP), the average molecular weight (MW) and the topological polar surface area (TPSA). The products in SMILES/pickle formats and their descriptors are stored inside the database. Finally, the building blocks and products are exported to downloadable SDF and SMILES files.</p>
      </sec>
      <sec id="SEC3-2-6">
        <title>Statistics of raw chemical library</title>
        <p>At each step of the library generation, counters are implemented for individual reactions to report statistics, including the number of reacted building blocks, the number of raw products, the number of duplicates and the number of final unique products. These reaction-specific counters are merged to derive overall statistics for the generated chemical library.</p>
      </sec>
    </sec>
    <sec id="SEC3-3">
      <title>Post-processing stage</title>
      <sec id="SEC3-3-1">
        <title>Filtering using physico-chemical descriptors</title>
        <p>Histograms showing the frequency distribution of compounds are produced using molecular descriptors computed during the raw library generation. For discrete descriptors (HBA, HBD), a single bin is assigned for each unique value within the range of the descriptor. In the case of continuous descriptors (Fsp<sup>3</sup>, cLogP, MW, TPSA) 15 bins are specified. Then, the number of compounds matching a user-defined interval is computed in real time for each descriptor. This involves querying the database using descriptors indexes to retrieve the relevant information.</p>
      </sec>
      <sec id="SEC3-3-2">
        <title>Generation of 2D library</title>
        <p>The available products are collected from the database, then filtered using the intervals defined during the post-processing stage, sorted by molecular weight, and exported to downloadable SMILES and SDF files.</p>
      </sec>
      <sec id="SEC3-3-3">
        <title>Generation of 3D library</title>
        <p>The filtered products are fetched from the database and the major microspecies are computed at pH 7 using a simplified pKa model derived from OpenBabel (<xref rid="B45" ref-type="bibr">45</xref>). The protonation states predicted by OpenBabel are not always reliable. We intend to use other freely available tools in future versions. We are currently investigating different approaches including SPORES (<xref rid="B46" ref-type="bibr">46</xref>) and AI-based tools (<xref rid="B47" ref-type="bibr">47–49</xref>). An embedding step is performed to quickly generate a 3D conformation of the molecule with a correct geometry using ETKDG from RDKit (<xref rid="B50" ref-type="bibr">50</xref>). The validity of the generated conformations can be verified using PoseBusters, a Python package that performs standard quality checks using RDKit (<xref rid="B51" ref-type="bibr">51</xref>). A 3D SDF file is then exported. In addition, the atom types are inferred according to Corina, and Gasteiger partial charges are computed to generate a ready-to-dock mol2 file. It is worth noting that, to reduce computational times, the energy of the generated conformers is currently not minimized using any forcefield. However, we are actively exploring the addition of an optional step for efficient energy minimization to optimize the 3D structure of the generated molecules.</p>
      </sec>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>Program description</title>
    <sec id="SEC4-1">
      <title>Design of the raw focused virtual library</title>
      <p>The overall workflow for designing the raw virtual library can be divided into 4 main steps summarized in Figure <xref rid="F1" ref-type="fig">1</xref>. First, the user must draw or upload the structure of the initial fragment (Figure <xref rid="F1" ref-type="fig">1A</xref>) using the provided Marvin JS sketcher from ChemAxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The SMILES code of the user-defined molecule is automatically generated. It is important to note that this reference fragment should contain at least one chemical function compatible with the fragment growing approach. A list of compatible functions is provided via the ‘Reactions’ link on the website, as well as in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> and <xref rid="sup1" ref-type="supplementary-material">S2</xref> and in <xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>. Two examples of molecules are provided to assist the user and can be directly imported into the sketcher (Figure <xref rid="F1" ref-type="fig">1A</xref>). In the next step, chemical functions present in the provided molecule are automatically detected and highlighted in the sketcher upon selection (Figure <xref rid="F1" ref-type="fig">1B</xref>). Users are then prompted to choose the chemical function for the fragment growing approach. For each chemical function, a list of compatible chemical reactions is provided (Figure <xref rid="F1" ref-type="fig">1C</xref>). These chemical reactions are derived in part from the 58 reactions compiled by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). The comprehensive list of reactions used in ChemoDOTS, along with their SMARTS representations, is available in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>. These chemical reactions are categorized into three groups based on their relevance. Users are required to select at least one compatible chemical reaction before proceeding to the next step. In the next step, a summary is provided, including the 2D structure of the initial fragment, key molecular descriptors, the SMILES code, the chemical function for fragment growing, and the selected compatible chemical reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the generation of virtual libraries workflow. (<bold>A</bold>) First, the user is prompted to draw or upload the structure of the initial hit fragment into the Marvin JS sketcher. Standard formats such as SMILES, SDF, or PDB are recognized. (<bold>B</bold>) In the second step, all chemical functions compatible with the growing mode are automatically detected. The user should select the desired function for growing. (<bold>C</bold>) All chemical reactions compatible with the chosen chemical function are shown. They are subdivided into three categories depending on their relevance. A text box is provided to search for specific chemical reactions using rule ID numbers or keywords. The different chemical reactions can be highlighted by hovering on the information icons. The user should select at least one chemical reaction before proceeding to the next step. For example, they may choose to perform sulfonamidation, such as the chemical reaction between a primary alkylamine and sulfonyl chlorides (rule 48 defined by Hartenfeller). (<bold>D</bold>) A summary of the selected input is provided along with key molecular descriptors commonly used in early drug discovery. The user should select the building block database that will be used to generate the focused chemical libraries. The raw libraries are generated in seconds to minutes depending on the number of reactions selected and the number of compatible building blocks. In the given example, all selected building blocks contain a sulfonyl chloride function.</p>
        </caption>
        <graphic xlink:href="gkae326fig1" position="float"/>
      </fig>
      <p>In the current version, the database contains 501 542 BBs from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) and 988 112 from Enamine (<ext-link xlink:href="https://enamine.net/building-blocks" ext-link-type="uri">https://enamine.net/building-blocks</ext-link>). In future releases, we plan to incorporate collections of BBs from other providers such as ChemDiv (<ext-link xlink:href="https://www.chemdiv.com/catalog/building-blocks" ext-link-type="uri">https://www.chemdiv.com/catalog/building-blocks</ext-link>), ChemSpace (<ext-link xlink:href="https://chem-space.com/building-blocks" ext-link-type="uri">https://chem-space.com/building-blocks</ext-link>) or Otava (<ext-link xlink:href="https://www.otavachemicals.com/products/chemical-building-blocks" ext-link-type="uri">https://www.otavachemicals.com/products/chemical-building-blocks</ext-link>). Additionally, we aim to enable users to upload their own collections of BBs.</p>
      <p>All compounds compatible with the selected parameters are then generated within seconds to minutes depending on the number of BBs that are compatible with the chosen reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>). On average 1000–1500 compounds are generated per second.</p>
    </sec>
    <sec id="SEC4-2">
      <title>Statistics of the raw library</title>
      <p>Upon generating the raw virtual library, a new page is displayed presenting general statistics about the library such as the number of generated compounds and duplicates. For each selected reaction, similar statistics are provided along with its overall contribution to the entire chemical space of the raw library. In addition, a subset of the generated compounds can be displayed in 2D format. At this stage, the raw library and the corresponding BBs can be downloaded in SDF and SMILES formats.</p>
    </sec>
    <sec id="SEC4-3">
      <title>Postprocessing</title>
      <p>The subsequent steps are optional and are highlighted in Figure <xref rid="F2" ref-type="fig">2</xref>. In the post-processing stages, users have the possibility to fine-tune the drug-like properties of the compounds in the virtual library. The distributions of six key molecular descriptors are available encompassing MW, cLogP, HBD, HBA, TPSA, and Fsp<sup>3</sup>. Additional common descriptors will be added in future release or upon request. Users can easily modify the range of each value by using the graphical sliders provided below each plot. The filtered chemical library can then be downloaded in SDF and SMILES formats.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Postprocessing of the raw chemical library. The raw library generated in the initial stage of the process can be refined by adjusting molecular descriptors commonly used in the early phases of drug discovery. These descriptors include molecular weight (MW), logarithm of n-octanol-water partition (cLogP), topological polar surface area (TPSA), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), and fraction of sp<sup>3</sup> carbons (Fsp<sup>3</sup>), an indicator of the three dimensionality of molecules. For each property, the distribution is displayed, and a slider allows users to adjust the minimum and maximum values of each descriptor. The total number of molecules in the filtered library is automatically updated.</p>
        </caption>
        <graphic xlink:href="gkae326fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC4-4">
      <title>Generation of ready-to-dock files</title>
      <p>In the last step, major microspecies, atomic types, partial charges, and one 3D-conformer of each compound in the virtual library are computed. The resulting final 3D library can be downloaded in SDF and ready-to-dock mol2 formats.</p>
    </sec>
    <sec id="SEC4-5">
      <title>Retrospective case study</title>
      <p>We previously engaged in a fragment-based drug design program followed by hit-to-lead optimization to develop chemical probes targeting bromodomain proteins from the BET family (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B52" ref-type="bibr">52</xref>). Bromodomains are protein modules that play a crucial role in gene regulation by recognizing and binding to acetylated lysine residues on histone proteins. The development of bromodomain inhibitors is a promising strategy in cancer treatment offering a targeted approach to modulate gene expression and hinder the growth of cancer cells by disrupting crucial molecular interactions involved in the regulation of gene transcription. Briefly, several primary hits were identified through high throughput screening of an in-house chemical library dedicated to protein–protein interactions (<xref rid="B52" ref-type="bibr">52</xref>). The most potent inhibitor (K<sub>D</sub> ≈ 1.4 μM) was deconstructed, and its affinity was improved using structure–activity relationship (SAR) studies (Figure <xref rid="F3" ref-type="fig">3A</xref>). The resulting fragment was activated with a primary amine to allow growing optimization using our in-house strategy that combines virtual screening with automated real-world synthesis in a platform called Diversity-Oriented Target-focused Synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). This study led to the design of 17 compounds with improved affinities. The affinity of the most potent compound was improved more than 60 times compared to the initial fragment and its binding mode was validated by X-ray crystallography (PDB: 6FO5) (<xref rid="B36" ref-type="bibr">36</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Case study using a retrospective identification of bromodomain inhibitors. (<bold>A</bold>) We previously identified a xanthin derivative inhibitor of bromodomains through high throughput screening (<xref rid="B52" ref-type="bibr">52</xref>). This primary hit (K<sub>D</sub> ≈ 1.4 μM) was deconstructed to find the smallest fragment able to bind the target. This fragment was optimized and activated with a reactive primary amino group (<xref rid="B36" ref-type="bibr">36</xref>). Subsequently, this activated fragment was optimized using our <italic toggle="yes">in-house</italic> hit-to-lead approach called DOTS resulting in 17 compounds with improved affinities including a sub-micromolar probe exhibiting almost a 2-log improvement (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>). (<bold>B</bold>) To test the ability to generate such compounds, the activated fragment was uploaded in SMILES format on the ChemoDOTS server. The primary alkylamine function was automatically detected as the only reactive function on the molecule. The sulfonamide reaction and the MolPort BBs were then selected to generate the raw virtual library resulting in 5546 sulfonamide derivatives. A post-processing filtering was applied to lead to 3644 compounds which include all 17 optimized compounds identified during the hit-to-lead optimization.</p>
        </caption>
        <graphic xlink:href="gkae326fig3" position="float"/>
      </fig>
      <p>We tested the ability of ChemoDOTS to generate these compounds. The initial fragment activated with a reactive primary amine function was uploaded into the Marvin JS sketcher (Figure <xref rid="F3" ref-type="fig">3B</xref>). As expected, the primary amine function was automatically detected as the only chemical function on the fragment. We then selected the sulfonamidation reaction (#48 from Hartenfeller set of reactions) and the MolPort BBs to generate the raw chemical library. The process resulted in 5546 molecules in 5 s after removal of duplicates. We then applied a standard filtering step using Lipinski-like thresholds (MW &lt; 550 g mol<sup>−1</sup>; log <italic toggle="yes">P</italic> &lt; 5; number of hydrogen bond donors &lt; 5; number of hydrogen bond acceptors &lt; 10) leading to 3644 molecules. All 17 compounds previously identified during the hit-to-lead optimization were present in the final virtual library. All files generated during this retrospective case have been deposited in a zenodo archive (<ext-link xlink:href="https://doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC5">
    <title>Discussion</title>
    <p>In summary, ChemoDOTS is a user-friendly web server that enables the generation and exploration of a vast chemical space around an initial hit molecule by combining molecular building blocks and predefined chemistry rules. Over the last few years, the concept of large chemical space exploration has come to the forefront of drug discovery (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B53" ref-type="bibr">53</xref>). All compounds in the raw virtual library should be easily amenable to organic synthesis in one or two steps. This is achieved by using a collection of robust chemical reactions commonly used in the hit-to-lead optimization phase in the pharmaceutical industry. The drug-like properties of the generated compounds can be improved by adjusting various molecular descriptors. The final chemical library is ready for synthesis or further investigation using either ligand-based or structure-based virtual screening experiments. The high level of parallelization ensures the rapid generation of molecules at more than one thousand molecules generated per second. The global architecture of the server as a database allows efficient web server maintenance and scalability. The current version of ChemoDOTS relies on a collection of more than 500 000 BBs from MolPort and almost a million from Enamine. However, the virtual chemical space covered by ChemoDOTS can be easily extended through the integration of additional BBs from other providers or user-defined sources. Additionally, the incorporation of new chemical reactions including those used in click chemistry offers further avenues for expansion (<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>). The post-processing stage allows users to custom-filter the final collection of compounds by physico-chemical properties in line with the requirements of their drug discovery project. New molecular descriptors can be easily integrated at this stage in future releases of the server. We also anticipate benefiting from users’ feedback to upgrade ChemoDOTS and to deliver a better service. To our knowledge, ChemoDOTS is the only freely accessible functional and maintained web server to combine the design of medchem-compatible focused virtual libraries with an integrated graphical postprocessing analysis. Therefore, it creates a valuable resource for scientists engaged in H2L optimization, particularly for those who may lack the chemoinformatics knowledge required for tasks such as library enumeration, filtering and preparation for subsequent docking experiments.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkae326_Supplemental_File</label>
      <media xlink:href="gkae326_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We express our gratitude to Dr Aznam Yacoub and Namarta Vij from the School of Computer Science (University of Windsor, Canada) for their valuable contribution to the design of the web server's frontend. Special thanks go to Dr Samuel Granjeaud for his help and guidance in web developments. Our appreciation extends to Drs Sébastien Abel, Paul Brémond and Sébastien Combes for their insightful discussions about the chemical reactions used in ChemoDOTS. We would also like to thank Drs Dominique Douguet and Magali Saez Ayala for testing the web server. Lastly, we extend our thanks to the DISC platform for providing the facilities to host the ChemoDOTS web server.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC6">
    <title>Data availability</title>
    <p>The ChemoDOTS web server is freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. All scripts used in ChemoDOTS backend have been deposited on GitHub (<ext-link xlink:href="https://github.com/iSCBTeam/ChemoDOTS" ext-link-type="uri">https://github.com/iSCBTeam/ChemoDOTS</ext-link>). Permanent DOI of the code used for ChemoDOTS: Backend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585089" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585089</ext-link> Frontend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585092" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585092</ext-link> The list of chemical functions, the list of reactions, and the final BBs from MolPort and Enamine (in SMILES format) are available via Zenodo repository at <ext-link xlink:href="https://doi.org/10.5281/zenodo.10776787" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10776787</ext-link>. Files from the retrospective test case can be accessed through the Zenodo repository at <ext-link xlink:href="https://dx.doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>.</p>
  </sec>
  <sec id="SEC7">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkae326#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC8">
    <title>Funding</title>
    <p>Agence Nationale de la Recherche [ANR-20-CE18-0025, ANR-21-CE18-0056, ANR-22-CE18-0023]; National Cancer Institute [R37 CA218259 to T.W.M.]; G.C. is funded by ANR-22-CE18-0023. Funding for open access charge: Agence Nationale de la Recherche [ANR-21-CE18-0056].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Laurent Hoffer, Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.</p>
  </notes>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name></person-group>  <article-title>Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches</article-title>. <source>Mol. Inform.</source>  <year>2018</year>; <volume>37</volume>:<fpage>e1800059</fpage>.<pub-id pub-id-type="pmid">30051601</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frye</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bhat</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Akinsanya</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>From computer-aided drug discovery to computer-driven drug discovery</article-title>. <source>Drug Discov. Today Technol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>111</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">34906321</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Souza Neto</surname>  <given-names>L.R.</given-names></string-name>, <string-name><surname>Moreira-Filho</surname>  <given-names>J.T.</given-names></string-name>, <string-name><surname>Neves</surname>  <given-names>B.J.</given-names></string-name>, <string-name><surname>Maidana</surname>  <given-names>R.L.B.R.</given-names></string-name>, <string-name><surname>Guimarães</surname>  <given-names>A.C.R.</given-names></string-name>, <string-name><surname>Furnham</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Andrade</surname>  <given-names>C.H.</given-names></string-name>, <string-name><surname>Silva</surname>  <given-names>F.P.</given-names></string-name></person-group>  <article-title>Strategies to support fragment-to-lead optimization in drug discovery</article-title>. <source>Front. Chem.</source>  <year>2020</year>; <volume>8</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">32133344</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Talevi</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Computer-aided drug discovery and design: recent advances and future prospects</article-title>. <source>Methods Mol. Biol.</source>  <year>2024</year>; <volume>2714</volume>:<fpage>1</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">37676590</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moret</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Clark</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Hafner</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Lounkine</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Medvedovic</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Jenkins</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sorger</surname>  <given-names>P.K.</given-names></string-name></person-group>  <article-title>Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries</article-title>. <source>Cell Chem. Biol.</source>  <year>2019</year>; <volume>26</volume>:<fpage>765</fpage>–<lpage>777</lpage>.<pub-id pub-id-type="pmid">30956147</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirsch</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hartman</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Hirsch</surname>  <given-names>A.K.H.</given-names></string-name>, <string-name><surname>Empting</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>Concepts and core principles of fragment-based drug design</article-title>. <source>Molecules</source>. <year>2019</year>; <volume>24</volume>:<fpage>4309</fpage>.<pub-id pub-id-type="pmid">31779114</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bienstock</surname>  <given-names>R.J.</given-names></string-name></person-group>  <article-title>Computational methods for fragment-based ligand design: growing and linking</article-title>. <source>Methods Mol. Biol.</source>  <year>2015</year>; <volume>1289</volume>:<fpage>119</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">25709037</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Polanski</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Bogocz</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Tkocz</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>The analysis of the market success of FDA approvals by probing top 100 bestselling drugs</article-title>. <source>J. Comput. Aided Mol. Des.</source>  <year>2016</year>; <volume>30</volume>:<fpage>381</fpage>–<lpage>389</lpage>.<pub-id pub-id-type="pmid">27125384</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hann</surname>  <given-names>M.M.</given-names></string-name></person-group>  <article-title>Molecular obesity, potency and other addictions in drug discovery</article-title>. <source>Med.Chem. Commun.</source>  <year>2011</year>; <volume>2</volume>:<fpage>349</fpage>–<lpage>355</lpage>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fry</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Wartchow</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Graves</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Janson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lukacs</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Kammlott</surname>  <given-names>U.</given-names></string-name>, <string-name><surname>Belunis</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Palme</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vu</surname>  <given-names>B.</given-names></string-name></person-group>  <article-title>Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2013</year>; <volume>4</volume>:<fpage>660</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">24900726</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Dong</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Sheng</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Structural simplification: an efficient strategy in lead optimization</article-title>. <source>Acta Pharm Sin B</source>. <year>2019</year>; <volume>9</volume>:<fpage>880</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">31649841</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferreira</surname>  <given-names>L.G.</given-names></string-name>, <string-name><surname>Andricopulo</surname>  <given-names>A.D.</given-names></string-name></person-group>  <article-title>From protein structure to small-molecules: recent advances and applications to fragment-based drug discovery</article-title>. <source>Curr. Top. Med. Chem.</source>  <year>2017</year>; <volume>17</volume>:<fpage>2260</fpage>–<lpage>2270</lpage>.<pub-id pub-id-type="pmid">28240184</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romasanta</surname>  <given-names>A.K.S.</given-names></string-name>, <string-name><surname>van der Sijde</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hellsten</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Keseru</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>van Muijlwijk-Koezen</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name></person-group>  <article-title>When fragments link: a bibliometric perspective on the development of fragment-based drug discovery</article-title>. <source>Drug Discov. Today</source>. <year>2018</year>; <volume>23</volume>:<fpage>1596</fpage>–<lpage>1609</lpage>.<pub-id pub-id-type="pmid">29738823</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walsh</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Woodhead</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Wren</surname>  <given-names>E.</given-names></string-name></person-group>  <article-title>Fragment-to-lead medicinal chemistry publications in 2021</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>1137</fpage>–<lpage>1156</lpage>.<pub-id pub-id-type="pmid">36622056</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>Fesik</surname>  <given-names>S.W.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>Twenty years on: the impact of fragments on drug discovery</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2016</year>; <volume>15</volume>:<fpage>605</fpage>–<lpage>619</lpage>.<pub-id pub-id-type="pmid">27417849</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Introduction to fragment-based drug discovery</article-title>. <source>Top. Curr. Chem.</source>  <year>2012</year>; <volume>317</volume>:<fpage>1</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">21695633</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Congreve</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Carr</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>A ‘rule of three’ for fragment-based lead discovery?</article-title>. <source>Drug Discov. Today</source>. <year>2003</year>; <volume>8</volume>:<fpage>876</fpage>–<lpage>877</lpage>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Williams</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Rees</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.W.</given-names></string-name></person-group>  <article-title>The ‘rule of three’ for fragment-based drug discovery: where are we now?</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2013</year>; <volume>12</volume>:<fpage>644</fpage>–<lpage>645</lpage>.<pub-id pub-id-type="pmid">23845999</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Renaud</surname>  <given-names>J.P.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>Fragment-based drug design: computational &amp; experimental state of the art</article-title>. <source>Comb. Chem. High Throughput Screen.</source>  <year>2011</year>; <volume>14</volume>:<fpage>500</fpage>–<lpage>520</lpage>.<pub-id pub-id-type="pmid">21521152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname>  <given-names>D.E.</given-names></string-name>, <string-name><surname>Coyne</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Hudson</surname>  <given-names>S.A.</given-names></string-name>, <string-name><surname>Abell</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Fragment-based approaches in drug discovery and chemical biology</article-title>. <source>Biochemistry</source>. <year>2012</year>; <volume>51</volume>:<fpage>4990</fpage>–<lpage>5003</lpage>.<pub-id pub-id-type="pmid">22697260</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Montfort</surname>  <given-names>R.L.M.</given-names></string-name>, <string-name><surname>Workman</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Structure-based drug design: aiming for a perfect fit</article-title>. <source>Essays Biochem.</source>  <year>2017</year>; <volume>61</volume>:<fpage>431</fpage>–<lpage>437</lpage>.<pub-id pub-id-type="pmid">29118091</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>Z.Z.</given-names></string-name>, <string-name><surname>Shi</surname>  <given-names>X.X.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>G.Y.</given-names></string-name>, <string-name><surname>Hao</surname>  <given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>G.F.</given-names></string-name></person-group>  <article-title>Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions</article-title>. <source>Trends Biochem. Sci.</source>  <year>2023</year>; <volume>48</volume>:<fpage>539</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">36841635</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>W.Y.</given-names></string-name></person-group>  <article-title>DFRscore: deep learning-based scoring of synthetic complexity with drug-focused retrosynthetic analysis for high-throughput virtual screening</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2023</year>; <volume>64</volume>:<fpage>2432</fpage>–<lpage>2444</lpage>.<pub-id pub-id-type="pmid">37651152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Eberle</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Meier</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Nieto-Oberhuber</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Altmann</surname>  <given-names>K.H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Jacoby</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Renner</surname>  <given-names>S.</given-names></string-name></person-group>  <article-title>A collection of robust organic synthesis reactions for in silico molecule design</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2011</year>; <volume>51</volume>:<fpage>3093</fpage>–<lpage>3098</lpage>.<pub-id pub-id-type="pmid">22077721</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Zettl</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Walter</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Rupp</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Reisen</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Proschak</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Weggen</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Stark</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>DOGS: reaction-driven de novo design of bioactive compounds</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002380</fpage>.<pub-id pub-id-type="pmid">22359493</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evers</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hessler</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>L.H.</given-names></string-name>, <string-name><surname>Werrel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Monecke</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Matter</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents</article-title>. <source>J. Med. Chem.</source>  <year>2013</year>; <volume>56</volume>:<fpage>4656</fpage>–<lpage>4670</lpage>.<pub-id pub-id-type="pmid">23627295</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic rractability</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>1824</fpage>–<lpage>1835</lpage>.<pub-id pub-id-type="pmid">26282054</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rimmer</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Betti</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Pardon</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Ballet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>van Hilten</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Steyaert</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Diederich</surname>  <given-names>W.E.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Binding-site compatible fragment growing applied to the design of β2-adrenergic receptor ligands</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>1118</fpage>–<lpage>1129</lpage>.<pub-id pub-id-type="pmid">29364664</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Batiste</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Unzue</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Dolbois</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hassler</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Deerain</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Zhu</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Spiliotopoulos</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Nevado</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Caflisch</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Chemical space expansion of bromodomain ligands guided by in silico virtual couplings (AutoCouple)</article-title>. <source>ACS Cent. Sci.</source>  <year>2018</year>; <volume>4</volume>:<fpage>180</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">29532017</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sommer</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Flachsenberg</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rarey</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>NAOMInext - synthetically feasible fragment growing in a structure-based design context</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>163</volume>:<fpage>747</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">30576905</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humbeck</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Weigang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Schäfer</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Mutzel</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Koch</surname>  <given-names>O.</given-names></string-name></person-group>  <article-title>CHIPMUNK: a virtual synthesizable small-molecule library for medicinal chemistry, exploitable for protein-protein interaction modulators</article-title>. <source>ChemMedChem</source>. <year>2018</year>; <volume>13</volume>:<fpage>532</fpage>–<lpage>539</lpage>.<pub-id pub-id-type="pmid">29392860</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daina</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Zoete</surname>  <given-names>V.</given-names></string-name></person-group>  <article-title>Application of the SwissDrugDesign online resources in virtual screening</article-title>. <source>Int. J. Mol. Sci.</source>  <year>2019</year>; <volume>20</volume>:<fpage>4612</fpage>.<pub-id pub-id-type="pmid">31540350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spiegel</surname>  <given-names>J.O.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title>. <source>J. Cheminform.</source>  <year>2020</year>; <volume>12</volume>:<fpage>25</fpage>.<pub-id pub-id-type="pmid">33431021</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wahl</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sander</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Fully automated creation of virtual chemical fragment spaces using the open-source library OpenChemLib</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2022</year>; <volume>62</volume>:<fpage>2202</fpage>–<lpage>2211</lpage>.<pub-id pub-id-type="pmid">35073086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neumann</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Marrison</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>Relevance of the trillion-sized chemical space “eXplore” as a source for drug discovery</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2023</year>; <volume>14</volume>:<fpage>466</fpage>–<lpage>472</lpage>.<pub-id pub-id-type="pmid">37077402</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.V.</given-names></string-name>, <string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Fedorov</surname>  <given-names>A.Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Amouric</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>5719</fpage>–<lpage>5732</lpage>.<pub-id pub-id-type="pmid">29883107</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Chira</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Marcou</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Varnek</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE – Sampler for Multiple Protein-Ligand Entities: methodology and rigid-site docking benchmarking</article-title>. <source>Molecules</source>. <year>2015</year>; <volume>20</volume>:<fpage>8997</fpage>–<lpage>9028</lpage>.<pub-id pub-id-type="pmid">25996209</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE–sampler for multiple protein-ligand entities: simultaneous docking of several entities</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2013</year>; <volume>53</volume>:<fpage>88</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">23215156</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hernandez</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Coutard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Querat</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Decroly</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>161</volume>:<fpage>323</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">30368131</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kashyap</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Kovalskyy</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ghossoub</surname>  <given-names>R.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loadifing with syndecan and EpCAM cargo</article-title>. <source>J. Extracell. Vesicles</source>. <year>2020</year>; <volume>10</volume>:<fpage>e12039</fpage>.<pub-id pub-id-type="pmid">33343836</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Benmansour</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2021</year>; <volume>223</volume>:<fpage>113601</fpage>.<pub-id pub-id-type="pmid">34153575</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Daulat</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Discovery of a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein interaction: a semi-automated “hit identification-to-optimization” approach</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>4633</fpage>–<lpage>4658</lpage>.<pub-id pub-id-type="pmid">36939673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Montersino</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Restouin</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Castellano</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Casassa</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Pasquier</surname>  <given-names>E.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>CRCM5484: a BET-BDII selective compound with differential anti-leukemic drug modulation</article-title>. <source>J. Med. Chem.</source>  <year>2022</year>; <volume>65</volume>:<fpage>5660</fpage>–<lpage>5674</lpage>.<pub-id pub-id-type="pmid">35348328</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Sicard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Andrieu</surname>  <given-names>G.P.</given-names></string-name>, <string-name><surname>Latiri</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Davison</surname>  <given-names>E.K.</given-names></string-name>, <string-name><surname>Ciufolini</surname>  <given-names>M.A.</given-names></string-name>, <string-name><surname>Brémond</surname>  <given-names>P.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia</article-title>. <source>Nat. Commun.</source>  <year>2023</year>; <volume>14</volume>:<fpage>3079</fpage>.<pub-id pub-id-type="pmid">37248212</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Boyle</surname>  <given-names>N.M.</given-names></string-name>, <string-name><surname>Banck</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>James</surname>  <given-names>C.A.</given-names></string-name>, <string-name><surname>Morley</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vandermeersch</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Hutchison</surname>  <given-names>G.R.</given-names></string-name></person-group>  <article-title>Open Babel: an open chemical toolbox</article-title>. <source>J. Cheminform.</source>  <year>2011</year>; <volume>3</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brink</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Exner</surname>  <given-names>T.E.</given-names></string-name></person-group>  <article-title>Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2009</year>; <volume>49</volume>:<fpage>1535</fpage>–<lpage>1546</lpage>.<pub-id pub-id-type="pmid">19453150</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayr</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Langer</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Improving small molecule pK</article-title>. <source>Front. Chem.</source>  <year>2022</year>; <volume>10</volume>:<fpage>866585</fpage>.<pub-id pub-id-type="pmid">35721000</pub-id>
</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ropp</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Kaminsky</surname>  <given-names>J.C.</given-names></string-name>, <string-name><surname>Yablonski</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>Dimorphite-DL: an open-source program for enumerating the ionization states of drug-like small molecules</article-title>. <source>J. Cheminform.</source>  <year>2019</year>; <volume>11</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">30767086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>J.Z.H.</given-names></string-name>, <string-name><surname>Ji</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>MolGpka: a web server for small molecule pKa prediction using a graph-convolutional neural network</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2021</year>; <volume>61</volume>:<fpage>3159</fpage>–<lpage>3165</lpage>.<pub-id pub-id-type="pmid">34251213</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riniker</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Landrum</surname>  <given-names>G.A.</given-names></string-name></person-group>  <article-title>Better informed distance geometry: using what we know to improve conformation generation</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>2562</fpage>–<lpage>2574</lpage>.<pub-id pub-id-type="pmid">26575315</pub-id>
</mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buttenschoen</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Morris</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>Deane</surname>  <given-names>C.M.</given-names></string-name></person-group>  <article-title>PoseBusters: aI-based docking methods fail to generate physically valid poses or generalise to novel sequences</article-title>. <source>Chem. Sci.</source>  <year>2024</year>; <volume>15</volume>:<fpage>3130</fpage>–<lpage>3139</lpage>.<pub-id pub-id-type="pmid">38425520</pub-id>
</mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lugari</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Rebuffet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Milhas</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Priet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Roux</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Trinquet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Guillemot</surname>  <given-names>J.C.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins</article-title>. <source>J. Med. Chem.</source>  <year>2016</year>; <volume>59</volume>:<fpage>1634</fpage>–<lpage>1641</lpage>.<pub-id pub-id-type="pmid">26735842</pub-id>
</mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Potlitz</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Link</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Schulig</surname>  <given-names>L.</given-names></string-name></person-group>  <article-title>Advances in the discovery of new chemotypes through ultra-large library docking</article-title>. <source>Expert Opin. Drug Discov.</source>  <year>2023</year>; <volume>18</volume>:<fpage>303</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">36714919</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name>, <string-name><surname>McCammon</surname>  <given-names>J.A.</given-names></string-name></person-group>  <article-title>AutoClickChem: click chemistry in silico</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002397</fpage>.<pub-id pub-id-type="pmid">22438795</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massarotti</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Investigation of the click-chemical space for drug design using ZINClick</article-title>. <source>Methods Mol. Biol.</source>  <year>2021</year>; <volume>2266</volume>:<fpage>3</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33759118</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223810</article-id>
    <article-id pub-id-type="pmid">38686808</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae326</article-id>
    <article-id pub-id-type="publisher-id">gkae326</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemoDOTS: a web server to design chemistry-driven focused libraries</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1906-7128</contrib-id>
        <name>
          <surname>Hoffer</surname>
          <given-names>Laurent</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2806-8675</contrib-id>
        <name>
          <surname>Charifi-Hoareau</surname>
          <given-names>Guillaume</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1084-6312</contrib-id>
        <name>
          <surname>Barelier</surname>
          <given-names>Sarah</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5935-5058</contrib-id>
        <name>
          <surname>Betzi</surname>
          <given-names>Stéphane</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8645-2785</contrib-id>
        <name>
          <surname>Miller</surname>
          <given-names>Thomas</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9877-6058</contrib-id>
        <name>
          <surname>Morelli</surname>
          <given-names>Xavier</given-names>
        </name>
        <!--xavier.morelli@inserm.fr-->
        <xref rid="COR2" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5580-0588</contrib-id>
        <name>
          <surname>Roche</surname>
          <given-names>Philippe</given-names>
        </name>
        <!--philippe.roche@inserm.fr-->
        <xref rid="COR1" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +33 486 977 335; Fax: +33 486 977 499; Email: <email>philippe.roche@inserm.fr</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dr Xavier Morelli. Email: <email>xavier.morelli@inserm.fr</email></corresp>
      <fn id="FN1">
        <p>The first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-30">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W461</fpage>
    <lpage>W468</lpage>
    <history>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>11</day>
        <month>3</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae326.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>In drug discovery, the successful optimization of an initial hit compound into a lead molecule requires multiple cycles of chemical modification. Consequently, there is a need to efficiently generate synthesizable chemical libraries to navigate the chemical space surrounding the primary hit. To address this need, we introduce ChemoDOTS, an easy-to-use web server for hit-to-lead chemical optimization freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. With this tool, users enter an activated form of the initial hit molecule then choose from automatically detected reactive functions. The server proposes compatible chemical transformations via an ensemble of encoded chemical reactions widely used in the pharmaceutical industry during hit-to-lead optimization. After selection of the desired reactions, all compatible chemical building blocks are automatically coupled to the initial hit to generate a raw chemical library. Post-processing filters can be applied to extract a subset of compounds with specific physicochemical properties. Finally, explicit stereoisomers and tautomers are computed, and a 3D conformer is generated for each molecule. The resulting virtual library is compatible with most docking software for virtual screening campaigns. ChemoDOTS rapidly generates synthetically feasible, hit-focused, large, diverse chemical libraries with finely-tuned physicochemical properties via a user-friendly interface providing a powerful resource for researchers engaged in hit-to-lead optimization.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae326figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Agence Nationale de la Recherche</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001665</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ANR-20-CE18-0025</award-id>
        <award-id>ANR-21-CE18-0056</award-id>
        <award-id>ANR-22-CE18-0023</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R37 CA218259</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC2">
    <title>Introduction</title>
    <p>While the identification and validation of hit compounds is a nontrivial first step in the drug discovery process, these compounds normally require subsequent optimization to improve their efficacy, selectivity, and drug-like properties to become chemical probes or therapeutic candidates. During this optimization phase, vast chemical spaces are explored to find analogs or derivatives of the initial hit compounds with improved potency, selectivity, and better pharmacological properties. However, this hit-to-lead (H2L) optimization phase is usually a major bottleneck in drug discovery campaigns (<xref rid="B1" ref-type="bibr">1</xref>). Computational methods are increasingly being integrated into the H2L optimization process to aid in predicting compound properties, optimizing chemical structures, and prioritizing analogs for synthesis (<xref rid="B1" ref-type="bibr">1–5</xref>). One widely established approach to optimize validated hits is known as ‘growing’. This involves expanding chemical structures to introduce new interactions with the target, in order to improve potency and selectivity (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). However, a notable drawback emerges because of this strategy where the molecular weight of the compounds increases, outpacing gains in target affinity or activity, and leading to a phenomenon known as ‘molecular obesity’ (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). Therefore, it is crucial to initiate the H2L optimization phase with so-called ‘ligand-efficient’ molecules exhibiting a low molecular weight and high activity or potency. Such compounds can be obtained through the deconstruction or structural simplification of larger validated hit molecules (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>) or starting with lower molecular weight compounds. Therefore, fragment-based drug discovery (FBDD) appears as one of the most relevant approaches to identify initial hits (<xref rid="B12" ref-type="bibr">12–16</xref>). Fragments are low molecular weight chemical compounds defined by the rule of three (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). One of the key advantages of fragment libraries, compared to standard chemical libraries used in high-throughput screenings, lies in the fact that a small number of fragments can effectively represent a vast chemical space (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In addition, fragments also exhibit high hit rates compared to larger compounds. Because of the small size and low complexity of fragment molecules, FBDD is often combined with structure-based approaches to optimize the initial hits and increase their efficiency and specificity (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). One important aspect of the H2L optimization strategy is considering the synthetic feasibility of the designed compounds. Indeed, each iteration of the growing strategy, aimed at exploring the chemical space around the initial hit, involves synthesizing the designed analogs and testing them experimentally. Achieving this is typically performed through two main strategies. The synthetic feasibility can be estimated using machine learning approaches and expressed through a retrosynthetic score (<xref rid="B23" ref-type="bibr">23</xref>). Alternatively, carefully selected chemical reactions can be employed to virtually design potentially optimized compounds, as demonstrated by the curated collection proposed by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). In this collection, 58 medicinal chemistry-relevant chemical reactions commonly used during the H2L optimization stage in the pharmaceutical industry have been encoded in the machine-readable SMARTS format. These reactions have been implemented in several approaches including DOGS (<xref rid="B25" ref-type="bibr">25</xref>), CROSS (<xref rid="B26" ref-type="bibr">26</xref>), PINGUI/SCUBIDOO (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>), AutoCouple (<xref rid="B29" ref-type="bibr">29</xref>), NAOMINEXT (<xref rid="B30" ref-type="bibr">30</xref>), CHIPMUNK (<xref rid="B31" ref-type="bibr">31</xref>), SwissDrugDesign (<xref rid="B32" ref-type="bibr">32</xref>), AutoGrow4 (<xref rid="B33" ref-type="bibr">33</xref>), OpenChemLib (<xref rid="B34" ref-type="bibr">34</xref>) and eXplore (<xref rid="B35" ref-type="bibr">35</xref>). We also implemented this collection of reactions into our integrated drug design strategy called diversity-oriented target-focused synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). The DOTS approach combines the design of focused chemical libraries and virtual sampling to prioritize the best potential optimizations. Briefly, after hit identification and characterization of its binding mode using structural biophysics method, such as X-ray crystallography, a virtual library is generated. This is achieved by combining an activated core analog of a hit fragment, with a collection of functionalized building blocks (BBs) using the chemical reactions previously defined by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Post-processing stages are then applied to extract a diverse subset of representative compounds that possess reasonable physicochemical properties and are devoid of any undesirable chemical functions. The final library undergoes virtual screening with the S4MPLE tool (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>) to identify the best putative optimizations, aiming to create additional favorable contacts while maintaining the original binding mode. The DOTS approach has been successfully applied to various targets including the zika virus NS5 protein (<xref rid="B39" ref-type="bibr">39</xref>), syntenin PDZ domain protein (<xref rid="B40" ref-type="bibr">40–42</xref>), bromodomain-containing protein 4, BRD4 (<xref rid="B43" ref-type="bibr">43</xref>) and, more recently, a nucleotide kinase, dCK (<xref rid="B44" ref-type="bibr">44</xref>).</p>
    <p>As demonstrated above, the ensemble of chemical reactions defined by Hartenfeller <italic toggle="yes">et al.</italic> is widely used in the chemoinformatics community. However, there is currently no easy-to-use freely accessible web server able to efficiently generate large ready-to-dock virtual libraries using these chemical reactions. In response to this gap, we introduce the ChemoDOTS web server designed to facilitate the generation of focused virtual libraries starting from a user-defined activated fragment. The user first proceeds by uploading or drawing a hit fragment in a sketcher. The web server then automatically identifies the chemical functions that permit the virtual coupling of BBs on the starting molecule. The user then selects one of the identified chemical functions and chooses from a list of compatible chemical reactions. Subsequently, a raw chemical library corresponding to the given reactions and compatible BBs is generated. At this stage, the user is given the option to apply a detailed set of post-processing filters to extract drug-like compounds with specific physicochemical properties. The final stage involves the computation of explicit stereoisomers and tautomers and the generation of a 3D conformer for each compound. A resulting virtual library compatible with most docking software is supplied as mol2 files with atom types and partial charges. The web server is freely accessible to all users, including commercial users, at the following address <ext-link xlink:href="http://chemodots.marseille.inserm.fr/" ext-link-type="uri">http://chemodots.marseille.inserm.fr/</ext-link>.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC3">
    <title>Materials and methods</title>
    <sec id="SEC3-1">
      <title>Web server architecture</title>
      <p>The web server is composed of two parts: the frontend, which handles user interactions, and the backend, which performs the computations. The frontend is a single-page application (SPA) designed with the React framework and embedding the MarvinJS sketcher version 22.11.1 from Chemaxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The backend server is written in Rust to speed up response time. It runs under a virtualized (KVM) Linux instance with a 4 cores/8 hyperthreads Intel CPU, 32 GB of RAM and 90 GB of storage. It makes use of a PostgreSQL database to store all the internal data (e.g. chemical functions, encoded chemical reactions, building blocks) and user-submitted data.</p>
      <p>The raw compound references were stored separately from the building blocks to facilitate the treatment of duplicate molecules within or across providers while maintaining traceability. Chemical reactions, building blocks, and starting fragments were stored in their source/human readable format (SMARTS for reactions, SMILES for building blocks and fragments) to allow extensibility and direct compatibility with external tools. Additionally, they were stored in the RDkit pickle binary format which does not require sanitization and reduces loading time. Each operation was heavily parallelized using a thread pool across all available CPU cores to guarantee maximum performance. This was achieved through Rust's fearless concurrency mechanisms and the Rayon crate for parallel iterators. Database indexes were carefully defined to avoid computational bottlenecks without increasing the database size and reindexing workload for the database management system. To prevent unnecessary calculations, the list of building blocks available for each reaction was precomputed and stored within the database. The combined use of these optimizations allows fast chemical library generation producing at least 50 000 compounds per minute per reaction.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Generation of raw chemical library</title>
      <p>All the chemoinformatics operations are performed using the RDKit framework version 2023.09.5 (<ext-link xlink:href="https://www.rdkit.org/" ext-link-type="uri">https://www.rdkit.org/</ext-link>) unless otherwise stated.</p>
      <sec id="SEC3-2-1">
        <title>Preparation of building blocks</title>
        <p>The list of 626 026 commercially available building blocks as of 2024-02 was retrieved from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) as an SDF file. Then, a standardization pipeline was applied to discard undesirable compounds. First, for each compound, the largest organic fragment was selected discarding salts. The compounds containing only organic atoms (H, C, N, O, P, S), halogens (F, Cl, Br, I) or other atoms relevant in medicinal chemistry (B, Sn) were kept while explicit isotopes were filtered out. A series of filters were then applied to only retrieve BBs with &lt;2 unspecified stereocenters, less than 17 rotatable bonds to limit flexibility, less than 4 rings and between 5 and 24 heavy atoms to restrict the molecules size to an acceptable range. Finally, the compound charges were neutralized. The standardized building blocks were converted into canonical SMILES allowing duplicates to be identified and grouped together with the same internal reference. The resulting chemical structures were serialized using the RDKit pickle format for faster loading from database storage. In the end, 501 542 unique building blocks from MolPort were kept. The same pipeline was applied for the 1 254 866 commercially available building blocks as of 2024-02-05 from the Enamine comprehensive catalog (<ext-link xlink:href="https://enamine.net/building-blocks/building-blocks-catalog" ext-link-type="uri">https://enamine.net/building-blocks/building-blocks-catalog</ext-link>), resulting in the selection of 988 112 unique building blocks.</p>
      </sec>
      <sec id="SEC3-2-2">
        <title>Detection of reactive functions</title>
        <p>Reactive functions are detected by matching each building block against the chemical reactions. A substructure match is performed between an expected reactant template and a building block so that all the reacting building blocks for a given reaction are pre-identified and stored inside the database.</p>
      </sec>
      <sec id="SEC3-2-3">
        <title>List of chemical reactions</title>
        <p>The list of 58 SMART-encoded reactions was taken from the publication of Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Several in-house reactions (numbered 61–70) used in internal projects have been added to overcome some exceptions in the original list of reactions. The complete list of reactions and their corresponding SMARTS are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>.</p>
      </sec>
      <sec id="SEC3-2-4">
        <title>Detection of compatible chemical reactions</title>
        <p>To identify reactions compatible with a selected chemical function on a provided fragment, the reactant templates from the reaction SMARTS are matched against the fragment to identify the reacting atoms. Only reactions for which one template shares at least one common atom with the function are kept.</p>
      </sec>
      <sec id="SEC3-2-5">
        <title>Generation of raw chemical library</title>
        <p>All fragment atoms not involved in the reaction are masked to prevent reactions with unwanted functions and to speed up the process. Next, the reaction products are generated. Building blocks leading to more than one distinct product are discarded. The products are then grouped by canonical SMILES to identify duplicates (if any) and the 2D coordinates are generated. At this stage, a set of molecular descriptors are computed. These descriptors are the fraction of sp<sup>3</sup> carbons over the total carbon count (Fsp<sup>3</sup>), the number of hydrogen bond donors (HBD), the number of hydrogen bond acceptors (HBA), the logarithm of the predicted partition coefficient between octanol and water (cLogP), the average molecular weight (MW) and the topological polar surface area (TPSA). The products in SMILES/pickle formats and their descriptors are stored inside the database. Finally, the building blocks and products are exported to downloadable SDF and SMILES files.</p>
      </sec>
      <sec id="SEC3-2-6">
        <title>Statistics of raw chemical library</title>
        <p>At each step of the library generation, counters are implemented for individual reactions to report statistics, including the number of reacted building blocks, the number of raw products, the number of duplicates and the number of final unique products. These reaction-specific counters are merged to derive overall statistics for the generated chemical library.</p>
      </sec>
    </sec>
    <sec id="SEC3-3">
      <title>Post-processing stage</title>
      <sec id="SEC3-3-1">
        <title>Filtering using physico-chemical descriptors</title>
        <p>Histograms showing the frequency distribution of compounds are produced using molecular descriptors computed during the raw library generation. For discrete descriptors (HBA, HBD), a single bin is assigned for each unique value within the range of the descriptor. In the case of continuous descriptors (Fsp<sup>3</sup>, cLogP, MW, TPSA) 15 bins are specified. Then, the number of compounds matching a user-defined interval is computed in real time for each descriptor. This involves querying the database using descriptors indexes to retrieve the relevant information.</p>
      </sec>
      <sec id="SEC3-3-2">
        <title>Generation of 2D library</title>
        <p>The available products are collected from the database, then filtered using the intervals defined during the post-processing stage, sorted by molecular weight, and exported to downloadable SMILES and SDF files.</p>
      </sec>
      <sec id="SEC3-3-3">
        <title>Generation of 3D library</title>
        <p>The filtered products are fetched from the database and the major microspecies are computed at pH 7 using a simplified pKa model derived from OpenBabel (<xref rid="B45" ref-type="bibr">45</xref>). The protonation states predicted by OpenBabel are not always reliable. We intend to use other freely available tools in future versions. We are currently investigating different approaches including SPORES (<xref rid="B46" ref-type="bibr">46</xref>) and AI-based tools (<xref rid="B47" ref-type="bibr">47–49</xref>). An embedding step is performed to quickly generate a 3D conformation of the molecule with a correct geometry using ETKDG from RDKit (<xref rid="B50" ref-type="bibr">50</xref>). The validity of the generated conformations can be verified using PoseBusters, a Python package that performs standard quality checks using RDKit (<xref rid="B51" ref-type="bibr">51</xref>). A 3D SDF file is then exported. In addition, the atom types are inferred according to Corina, and Gasteiger partial charges are computed to generate a ready-to-dock mol2 file. It is worth noting that, to reduce computational times, the energy of the generated conformers is currently not minimized using any forcefield. However, we are actively exploring the addition of an optional step for efficient energy minimization to optimize the 3D structure of the generated molecules.</p>
      </sec>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>Program description</title>
    <sec id="SEC4-1">
      <title>Design of the raw focused virtual library</title>
      <p>The overall workflow for designing the raw virtual library can be divided into 4 main steps summarized in Figure <xref rid="F1" ref-type="fig">1</xref>. First, the user must draw or upload the structure of the initial fragment (Figure <xref rid="F1" ref-type="fig">1A</xref>) using the provided Marvin JS sketcher from ChemAxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The SMILES code of the user-defined molecule is automatically generated. It is important to note that this reference fragment should contain at least one chemical function compatible with the fragment growing approach. A list of compatible functions is provided via the ‘Reactions’ link on the website, as well as in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> and <xref rid="sup1" ref-type="supplementary-material">S2</xref> and in <xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>. Two examples of molecules are provided to assist the user and can be directly imported into the sketcher (Figure <xref rid="F1" ref-type="fig">1A</xref>). In the next step, chemical functions present in the provided molecule are automatically detected and highlighted in the sketcher upon selection (Figure <xref rid="F1" ref-type="fig">1B</xref>). Users are then prompted to choose the chemical function for the fragment growing approach. For each chemical function, a list of compatible chemical reactions is provided (Figure <xref rid="F1" ref-type="fig">1C</xref>). These chemical reactions are derived in part from the 58 reactions compiled by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). The comprehensive list of reactions used in ChemoDOTS, along with their SMARTS representations, is available in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>. These chemical reactions are categorized into three groups based on their relevance. Users are required to select at least one compatible chemical reaction before proceeding to the next step. In the next step, a summary is provided, including the 2D structure of the initial fragment, key molecular descriptors, the SMILES code, the chemical function for fragment growing, and the selected compatible chemical reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the generation of virtual libraries workflow. (<bold>A</bold>) First, the user is prompted to draw or upload the structure of the initial hit fragment into the Marvin JS sketcher. Standard formats such as SMILES, SDF, or PDB are recognized. (<bold>B</bold>) In the second step, all chemical functions compatible with the growing mode are automatically detected. The user should select the desired function for growing. (<bold>C</bold>) All chemical reactions compatible with the chosen chemical function are shown. They are subdivided into three categories depending on their relevance. A text box is provided to search for specific chemical reactions using rule ID numbers or keywords. The different chemical reactions can be highlighted by hovering on the information icons. The user should select at least one chemical reaction before proceeding to the next step. For example, they may choose to perform sulfonamidation, such as the chemical reaction between a primary alkylamine and sulfonyl chlorides (rule 48 defined by Hartenfeller). (<bold>D</bold>) A summary of the selected input is provided along with key molecular descriptors commonly used in early drug discovery. The user should select the building block database that will be used to generate the focused chemical libraries. The raw libraries are generated in seconds to minutes depending on the number of reactions selected and the number of compatible building blocks. In the given example, all selected building blocks contain a sulfonyl chloride function.</p>
        </caption>
        <graphic xlink:href="gkae326fig1" position="float"/>
      </fig>
      <p>In the current version, the database contains 501 542 BBs from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) and 988 112 from Enamine (<ext-link xlink:href="https://enamine.net/building-blocks" ext-link-type="uri">https://enamine.net/building-blocks</ext-link>). In future releases, we plan to incorporate collections of BBs from other providers such as ChemDiv (<ext-link xlink:href="https://www.chemdiv.com/catalog/building-blocks" ext-link-type="uri">https://www.chemdiv.com/catalog/building-blocks</ext-link>), ChemSpace (<ext-link xlink:href="https://chem-space.com/building-blocks" ext-link-type="uri">https://chem-space.com/building-blocks</ext-link>) or Otava (<ext-link xlink:href="https://www.otavachemicals.com/products/chemical-building-blocks" ext-link-type="uri">https://www.otavachemicals.com/products/chemical-building-blocks</ext-link>). Additionally, we aim to enable users to upload their own collections of BBs.</p>
      <p>All compounds compatible with the selected parameters are then generated within seconds to minutes depending on the number of BBs that are compatible with the chosen reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>). On average 1000–1500 compounds are generated per second.</p>
    </sec>
    <sec id="SEC4-2">
      <title>Statistics of the raw library</title>
      <p>Upon generating the raw virtual library, a new page is displayed presenting general statistics about the library such as the number of generated compounds and duplicates. For each selected reaction, similar statistics are provided along with its overall contribution to the entire chemical space of the raw library. In addition, a subset of the generated compounds can be displayed in 2D format. At this stage, the raw library and the corresponding BBs can be downloaded in SDF and SMILES formats.</p>
    </sec>
    <sec id="SEC4-3">
      <title>Postprocessing</title>
      <p>The subsequent steps are optional and are highlighted in Figure <xref rid="F2" ref-type="fig">2</xref>. In the post-processing stages, users have the possibility to fine-tune the drug-like properties of the compounds in the virtual library. The distributions of six key molecular descriptors are available encompassing MW, cLogP, HBD, HBA, TPSA, and Fsp<sup>3</sup>. Additional common descriptors will be added in future release or upon request. Users can easily modify the range of each value by using the graphical sliders provided below each plot. The filtered chemical library can then be downloaded in SDF and SMILES formats.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Postprocessing of the raw chemical library. The raw library generated in the initial stage of the process can be refined by adjusting molecular descriptors commonly used in the early phases of drug discovery. These descriptors include molecular weight (MW), logarithm of n-octanol-water partition (cLogP), topological polar surface area (TPSA), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), and fraction of sp<sup>3</sup> carbons (Fsp<sup>3</sup>), an indicator of the three dimensionality of molecules. For each property, the distribution is displayed, and a slider allows users to adjust the minimum and maximum values of each descriptor. The total number of molecules in the filtered library is automatically updated.</p>
        </caption>
        <graphic xlink:href="gkae326fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC4-4">
      <title>Generation of ready-to-dock files</title>
      <p>In the last step, major microspecies, atomic types, partial charges, and one 3D-conformer of each compound in the virtual library are computed. The resulting final 3D library can be downloaded in SDF and ready-to-dock mol2 formats.</p>
    </sec>
    <sec id="SEC4-5">
      <title>Retrospective case study</title>
      <p>We previously engaged in a fragment-based drug design program followed by hit-to-lead optimization to develop chemical probes targeting bromodomain proteins from the BET family (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B52" ref-type="bibr">52</xref>). Bromodomains are protein modules that play a crucial role in gene regulation by recognizing and binding to acetylated lysine residues on histone proteins. The development of bromodomain inhibitors is a promising strategy in cancer treatment offering a targeted approach to modulate gene expression and hinder the growth of cancer cells by disrupting crucial molecular interactions involved in the regulation of gene transcription. Briefly, several primary hits were identified through high throughput screening of an in-house chemical library dedicated to protein–protein interactions (<xref rid="B52" ref-type="bibr">52</xref>). The most potent inhibitor (K<sub>D</sub> ≈ 1.4 μM) was deconstructed, and its affinity was improved using structure–activity relationship (SAR) studies (Figure <xref rid="F3" ref-type="fig">3A</xref>). The resulting fragment was activated with a primary amine to allow growing optimization using our in-house strategy that combines virtual screening with automated real-world synthesis in a platform called Diversity-Oriented Target-focused Synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). This study led to the design of 17 compounds with improved affinities. The affinity of the most potent compound was improved more than 60 times compared to the initial fragment and its binding mode was validated by X-ray crystallography (PDB: 6FO5) (<xref rid="B36" ref-type="bibr">36</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Case study using a retrospective identification of bromodomain inhibitors. (<bold>A</bold>) We previously identified a xanthin derivative inhibitor of bromodomains through high throughput screening (<xref rid="B52" ref-type="bibr">52</xref>). This primary hit (K<sub>D</sub> ≈ 1.4 μM) was deconstructed to find the smallest fragment able to bind the target. This fragment was optimized and activated with a reactive primary amino group (<xref rid="B36" ref-type="bibr">36</xref>). Subsequently, this activated fragment was optimized using our <italic toggle="yes">in-house</italic> hit-to-lead approach called DOTS resulting in 17 compounds with improved affinities including a sub-micromolar probe exhibiting almost a 2-log improvement (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>). (<bold>B</bold>) To test the ability to generate such compounds, the activated fragment was uploaded in SMILES format on the ChemoDOTS server. The primary alkylamine function was automatically detected as the only reactive function on the molecule. The sulfonamide reaction and the MolPort BBs were then selected to generate the raw virtual library resulting in 5546 sulfonamide derivatives. A post-processing filtering was applied to lead to 3644 compounds which include all 17 optimized compounds identified during the hit-to-lead optimization.</p>
        </caption>
        <graphic xlink:href="gkae326fig3" position="float"/>
      </fig>
      <p>We tested the ability of ChemoDOTS to generate these compounds. The initial fragment activated with a reactive primary amine function was uploaded into the Marvin JS sketcher (Figure <xref rid="F3" ref-type="fig">3B</xref>). As expected, the primary amine function was automatically detected as the only chemical function on the fragment. We then selected the sulfonamidation reaction (#48 from Hartenfeller set of reactions) and the MolPort BBs to generate the raw chemical library. The process resulted in 5546 molecules in 5 s after removal of duplicates. We then applied a standard filtering step using Lipinski-like thresholds (MW &lt; 550 g mol<sup>−1</sup>; log <italic toggle="yes">P</italic> &lt; 5; number of hydrogen bond donors &lt; 5; number of hydrogen bond acceptors &lt; 10) leading to 3644 molecules. All 17 compounds previously identified during the hit-to-lead optimization were present in the final virtual library. All files generated during this retrospective case have been deposited in a zenodo archive (<ext-link xlink:href="https://doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC5">
    <title>Discussion</title>
    <p>In summary, ChemoDOTS is a user-friendly web server that enables the generation and exploration of a vast chemical space around an initial hit molecule by combining molecular building blocks and predefined chemistry rules. Over the last few years, the concept of large chemical space exploration has come to the forefront of drug discovery (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B53" ref-type="bibr">53</xref>). All compounds in the raw virtual library should be easily amenable to organic synthesis in one or two steps. This is achieved by using a collection of robust chemical reactions commonly used in the hit-to-lead optimization phase in the pharmaceutical industry. The drug-like properties of the generated compounds can be improved by adjusting various molecular descriptors. The final chemical library is ready for synthesis or further investigation using either ligand-based or structure-based virtual screening experiments. The high level of parallelization ensures the rapid generation of molecules at more than one thousand molecules generated per second. The global architecture of the server as a database allows efficient web server maintenance and scalability. The current version of ChemoDOTS relies on a collection of more than 500 000 BBs from MolPort and almost a million from Enamine. However, the virtual chemical space covered by ChemoDOTS can be easily extended through the integration of additional BBs from other providers or user-defined sources. Additionally, the incorporation of new chemical reactions including those used in click chemistry offers further avenues for expansion (<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>). The post-processing stage allows users to custom-filter the final collection of compounds by physico-chemical properties in line with the requirements of their drug discovery project. New molecular descriptors can be easily integrated at this stage in future releases of the server. We also anticipate benefiting from users’ feedback to upgrade ChemoDOTS and to deliver a better service. To our knowledge, ChemoDOTS is the only freely accessible functional and maintained web server to combine the design of medchem-compatible focused virtual libraries with an integrated graphical postprocessing analysis. Therefore, it creates a valuable resource for scientists engaged in H2L optimization, particularly for those who may lack the chemoinformatics knowledge required for tasks such as library enumeration, filtering and preparation for subsequent docking experiments.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkae326_Supplemental_File</label>
      <media xlink:href="gkae326_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We express our gratitude to Dr Aznam Yacoub and Namarta Vij from the School of Computer Science (University of Windsor, Canada) for their valuable contribution to the design of the web server's frontend. Special thanks go to Dr Samuel Granjeaud for his help and guidance in web developments. Our appreciation extends to Drs Sébastien Abel, Paul Brémond and Sébastien Combes for their insightful discussions about the chemical reactions used in ChemoDOTS. We would also like to thank Drs Dominique Douguet and Magali Saez Ayala for testing the web server. Lastly, we extend our thanks to the DISC platform for providing the facilities to host the ChemoDOTS web server.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC6">
    <title>Data availability</title>
    <p>The ChemoDOTS web server is freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. All scripts used in ChemoDOTS backend have been deposited on GitHub (<ext-link xlink:href="https://github.com/iSCBTeam/ChemoDOTS" ext-link-type="uri">https://github.com/iSCBTeam/ChemoDOTS</ext-link>). Permanent DOI of the code used for ChemoDOTS: Backend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585089" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585089</ext-link> Frontend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585092" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585092</ext-link> The list of chemical functions, the list of reactions, and the final BBs from MolPort and Enamine (in SMILES format) are available via Zenodo repository at <ext-link xlink:href="https://doi.org/10.5281/zenodo.10776787" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10776787</ext-link>. Files from the retrospective test case can be accessed through the Zenodo repository at <ext-link xlink:href="https://dx.doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>.</p>
  </sec>
  <sec id="SEC7">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkae326#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC8">
    <title>Funding</title>
    <p>Agence Nationale de la Recherche [ANR-20-CE18-0025, ANR-21-CE18-0056, ANR-22-CE18-0023]; National Cancer Institute [R37 CA218259 to T.W.M.]; G.C. is funded by ANR-22-CE18-0023. Funding for open access charge: Agence Nationale de la Recherche [ANR-21-CE18-0056].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Laurent Hoffer, Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.</p>
  </notes>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name></person-group>  <article-title>Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches</article-title>. <source>Mol. Inform.</source>  <year>2018</year>; <volume>37</volume>:<fpage>e1800059</fpage>.<pub-id pub-id-type="pmid">30051601</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frye</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bhat</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Akinsanya</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>From computer-aided drug discovery to computer-driven drug discovery</article-title>. <source>Drug Discov. Today Technol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>111</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">34906321</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Souza Neto</surname>  <given-names>L.R.</given-names></string-name>, <string-name><surname>Moreira-Filho</surname>  <given-names>J.T.</given-names></string-name>, <string-name><surname>Neves</surname>  <given-names>B.J.</given-names></string-name>, <string-name><surname>Maidana</surname>  <given-names>R.L.B.R.</given-names></string-name>, <string-name><surname>Guimarães</surname>  <given-names>A.C.R.</given-names></string-name>, <string-name><surname>Furnham</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Andrade</surname>  <given-names>C.H.</given-names></string-name>, <string-name><surname>Silva</surname>  <given-names>F.P.</given-names></string-name></person-group>  <article-title>Strategies to support fragment-to-lead optimization in drug discovery</article-title>. <source>Front. Chem.</source>  <year>2020</year>; <volume>8</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">32133344</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Talevi</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Computer-aided drug discovery and design: recent advances and future prospects</article-title>. <source>Methods Mol. Biol.</source>  <year>2024</year>; <volume>2714</volume>:<fpage>1</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">37676590</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moret</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Clark</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Hafner</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Lounkine</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Medvedovic</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Jenkins</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sorger</surname>  <given-names>P.K.</given-names></string-name></person-group>  <article-title>Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries</article-title>. <source>Cell Chem. Biol.</source>  <year>2019</year>; <volume>26</volume>:<fpage>765</fpage>–<lpage>777</lpage>.<pub-id pub-id-type="pmid">30956147</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirsch</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hartman</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Hirsch</surname>  <given-names>A.K.H.</given-names></string-name>, <string-name><surname>Empting</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>Concepts and core principles of fragment-based drug design</article-title>. <source>Molecules</source>. <year>2019</year>; <volume>24</volume>:<fpage>4309</fpage>.<pub-id pub-id-type="pmid">31779114</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bienstock</surname>  <given-names>R.J.</given-names></string-name></person-group>  <article-title>Computational methods for fragment-based ligand design: growing and linking</article-title>. <source>Methods Mol. Biol.</source>  <year>2015</year>; <volume>1289</volume>:<fpage>119</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">25709037</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Polanski</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Bogocz</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Tkocz</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>The analysis of the market success of FDA approvals by probing top 100 bestselling drugs</article-title>. <source>J. Comput. Aided Mol. Des.</source>  <year>2016</year>; <volume>30</volume>:<fpage>381</fpage>–<lpage>389</lpage>.<pub-id pub-id-type="pmid">27125384</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hann</surname>  <given-names>M.M.</given-names></string-name></person-group>  <article-title>Molecular obesity, potency and other addictions in drug discovery</article-title>. <source>Med.Chem. Commun.</source>  <year>2011</year>; <volume>2</volume>:<fpage>349</fpage>–<lpage>355</lpage>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fry</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Wartchow</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Graves</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Janson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lukacs</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Kammlott</surname>  <given-names>U.</given-names></string-name>, <string-name><surname>Belunis</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Palme</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vu</surname>  <given-names>B.</given-names></string-name></person-group>  <article-title>Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2013</year>; <volume>4</volume>:<fpage>660</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">24900726</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Dong</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Sheng</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Structural simplification: an efficient strategy in lead optimization</article-title>. <source>Acta Pharm Sin B</source>. <year>2019</year>; <volume>9</volume>:<fpage>880</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">31649841</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferreira</surname>  <given-names>L.G.</given-names></string-name>, <string-name><surname>Andricopulo</surname>  <given-names>A.D.</given-names></string-name></person-group>  <article-title>From protein structure to small-molecules: recent advances and applications to fragment-based drug discovery</article-title>. <source>Curr. Top. Med. Chem.</source>  <year>2017</year>; <volume>17</volume>:<fpage>2260</fpage>–<lpage>2270</lpage>.<pub-id pub-id-type="pmid">28240184</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romasanta</surname>  <given-names>A.K.S.</given-names></string-name>, <string-name><surname>van der Sijde</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hellsten</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Keseru</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>van Muijlwijk-Koezen</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name></person-group>  <article-title>When fragments link: a bibliometric perspective on the development of fragment-based drug discovery</article-title>. <source>Drug Discov. Today</source>. <year>2018</year>; <volume>23</volume>:<fpage>1596</fpage>–<lpage>1609</lpage>.<pub-id pub-id-type="pmid">29738823</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walsh</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Woodhead</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Wren</surname>  <given-names>E.</given-names></string-name></person-group>  <article-title>Fragment-to-lead medicinal chemistry publications in 2021</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>1137</fpage>–<lpage>1156</lpage>.<pub-id pub-id-type="pmid">36622056</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>Fesik</surname>  <given-names>S.W.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>Twenty years on: the impact of fragments on drug discovery</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2016</year>; <volume>15</volume>:<fpage>605</fpage>–<lpage>619</lpage>.<pub-id pub-id-type="pmid">27417849</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Introduction to fragment-based drug discovery</article-title>. <source>Top. Curr. Chem.</source>  <year>2012</year>; <volume>317</volume>:<fpage>1</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">21695633</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Congreve</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Carr</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>A ‘rule of three’ for fragment-based lead discovery?</article-title>. <source>Drug Discov. Today</source>. <year>2003</year>; <volume>8</volume>:<fpage>876</fpage>–<lpage>877</lpage>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Williams</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Rees</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.W.</given-names></string-name></person-group>  <article-title>The ‘rule of three’ for fragment-based drug discovery: where are we now?</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2013</year>; <volume>12</volume>:<fpage>644</fpage>–<lpage>645</lpage>.<pub-id pub-id-type="pmid">23845999</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Renaud</surname>  <given-names>J.P.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>Fragment-based drug design: computational &amp; experimental state of the art</article-title>. <source>Comb. Chem. High Throughput Screen.</source>  <year>2011</year>; <volume>14</volume>:<fpage>500</fpage>–<lpage>520</lpage>.<pub-id pub-id-type="pmid">21521152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname>  <given-names>D.E.</given-names></string-name>, <string-name><surname>Coyne</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Hudson</surname>  <given-names>S.A.</given-names></string-name>, <string-name><surname>Abell</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Fragment-based approaches in drug discovery and chemical biology</article-title>. <source>Biochemistry</source>. <year>2012</year>; <volume>51</volume>:<fpage>4990</fpage>–<lpage>5003</lpage>.<pub-id pub-id-type="pmid">22697260</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Montfort</surname>  <given-names>R.L.M.</given-names></string-name>, <string-name><surname>Workman</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Structure-based drug design: aiming for a perfect fit</article-title>. <source>Essays Biochem.</source>  <year>2017</year>; <volume>61</volume>:<fpage>431</fpage>–<lpage>437</lpage>.<pub-id pub-id-type="pmid">29118091</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>Z.Z.</given-names></string-name>, <string-name><surname>Shi</surname>  <given-names>X.X.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>G.Y.</given-names></string-name>, <string-name><surname>Hao</surname>  <given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>G.F.</given-names></string-name></person-group>  <article-title>Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions</article-title>. <source>Trends Biochem. Sci.</source>  <year>2023</year>; <volume>48</volume>:<fpage>539</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">36841635</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>W.Y.</given-names></string-name></person-group>  <article-title>DFRscore: deep learning-based scoring of synthetic complexity with drug-focused retrosynthetic analysis for high-throughput virtual screening</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2023</year>; <volume>64</volume>:<fpage>2432</fpage>–<lpage>2444</lpage>.<pub-id pub-id-type="pmid">37651152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Eberle</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Meier</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Nieto-Oberhuber</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Altmann</surname>  <given-names>K.H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Jacoby</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Renner</surname>  <given-names>S.</given-names></string-name></person-group>  <article-title>A collection of robust organic synthesis reactions for in silico molecule design</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2011</year>; <volume>51</volume>:<fpage>3093</fpage>–<lpage>3098</lpage>.<pub-id pub-id-type="pmid">22077721</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Zettl</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Walter</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Rupp</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Reisen</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Proschak</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Weggen</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Stark</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>DOGS: reaction-driven de novo design of bioactive compounds</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002380</fpage>.<pub-id pub-id-type="pmid">22359493</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evers</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hessler</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>L.H.</given-names></string-name>, <string-name><surname>Werrel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Monecke</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Matter</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents</article-title>. <source>J. Med. Chem.</source>  <year>2013</year>; <volume>56</volume>:<fpage>4656</fpage>–<lpage>4670</lpage>.<pub-id pub-id-type="pmid">23627295</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic rractability</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>1824</fpage>–<lpage>1835</lpage>.<pub-id pub-id-type="pmid">26282054</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rimmer</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Betti</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Pardon</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Ballet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>van Hilten</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Steyaert</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Diederich</surname>  <given-names>W.E.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Binding-site compatible fragment growing applied to the design of β2-adrenergic receptor ligands</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>1118</fpage>–<lpage>1129</lpage>.<pub-id pub-id-type="pmid">29364664</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Batiste</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Unzue</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Dolbois</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hassler</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Deerain</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Zhu</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Spiliotopoulos</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Nevado</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Caflisch</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Chemical space expansion of bromodomain ligands guided by in silico virtual couplings (AutoCouple)</article-title>. <source>ACS Cent. Sci.</source>  <year>2018</year>; <volume>4</volume>:<fpage>180</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">29532017</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sommer</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Flachsenberg</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rarey</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>NAOMInext - synthetically feasible fragment growing in a structure-based design context</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>163</volume>:<fpage>747</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">30576905</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humbeck</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Weigang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Schäfer</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Mutzel</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Koch</surname>  <given-names>O.</given-names></string-name></person-group>  <article-title>CHIPMUNK: a virtual synthesizable small-molecule library for medicinal chemistry, exploitable for protein-protein interaction modulators</article-title>. <source>ChemMedChem</source>. <year>2018</year>; <volume>13</volume>:<fpage>532</fpage>–<lpage>539</lpage>.<pub-id pub-id-type="pmid">29392860</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daina</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Zoete</surname>  <given-names>V.</given-names></string-name></person-group>  <article-title>Application of the SwissDrugDesign online resources in virtual screening</article-title>. <source>Int. J. Mol. Sci.</source>  <year>2019</year>; <volume>20</volume>:<fpage>4612</fpage>.<pub-id pub-id-type="pmid">31540350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spiegel</surname>  <given-names>J.O.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title>. <source>J. Cheminform.</source>  <year>2020</year>; <volume>12</volume>:<fpage>25</fpage>.<pub-id pub-id-type="pmid">33431021</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wahl</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sander</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Fully automated creation of virtual chemical fragment spaces using the open-source library OpenChemLib</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2022</year>; <volume>62</volume>:<fpage>2202</fpage>–<lpage>2211</lpage>.<pub-id pub-id-type="pmid">35073086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neumann</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Marrison</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>Relevance of the trillion-sized chemical space “eXplore” as a source for drug discovery</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2023</year>; <volume>14</volume>:<fpage>466</fpage>–<lpage>472</lpage>.<pub-id pub-id-type="pmid">37077402</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.V.</given-names></string-name>, <string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Fedorov</surname>  <given-names>A.Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Amouric</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>5719</fpage>–<lpage>5732</lpage>.<pub-id pub-id-type="pmid">29883107</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Chira</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Marcou</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Varnek</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE – Sampler for Multiple Protein-Ligand Entities: methodology and rigid-site docking benchmarking</article-title>. <source>Molecules</source>. <year>2015</year>; <volume>20</volume>:<fpage>8997</fpage>–<lpage>9028</lpage>.<pub-id pub-id-type="pmid">25996209</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE–sampler for multiple protein-ligand entities: simultaneous docking of several entities</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2013</year>; <volume>53</volume>:<fpage>88</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">23215156</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hernandez</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Coutard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Querat</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Decroly</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>161</volume>:<fpage>323</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">30368131</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kashyap</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Kovalskyy</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ghossoub</surname>  <given-names>R.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loadifing with syndecan and EpCAM cargo</article-title>. <source>J. Extracell. Vesicles</source>. <year>2020</year>; <volume>10</volume>:<fpage>e12039</fpage>.<pub-id pub-id-type="pmid">33343836</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Benmansour</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2021</year>; <volume>223</volume>:<fpage>113601</fpage>.<pub-id pub-id-type="pmid">34153575</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Daulat</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Discovery of a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein interaction: a semi-automated “hit identification-to-optimization” approach</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>4633</fpage>–<lpage>4658</lpage>.<pub-id pub-id-type="pmid">36939673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Montersino</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Restouin</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Castellano</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Casassa</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Pasquier</surname>  <given-names>E.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>CRCM5484: a BET-BDII selective compound with differential anti-leukemic drug modulation</article-title>. <source>J. Med. Chem.</source>  <year>2022</year>; <volume>65</volume>:<fpage>5660</fpage>–<lpage>5674</lpage>.<pub-id pub-id-type="pmid">35348328</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Sicard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Andrieu</surname>  <given-names>G.P.</given-names></string-name>, <string-name><surname>Latiri</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Davison</surname>  <given-names>E.K.</given-names></string-name>, <string-name><surname>Ciufolini</surname>  <given-names>M.A.</given-names></string-name>, <string-name><surname>Brémond</surname>  <given-names>P.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia</article-title>. <source>Nat. Commun.</source>  <year>2023</year>; <volume>14</volume>:<fpage>3079</fpage>.<pub-id pub-id-type="pmid">37248212</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Boyle</surname>  <given-names>N.M.</given-names></string-name>, <string-name><surname>Banck</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>James</surname>  <given-names>C.A.</given-names></string-name>, <string-name><surname>Morley</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vandermeersch</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Hutchison</surname>  <given-names>G.R.</given-names></string-name></person-group>  <article-title>Open Babel: an open chemical toolbox</article-title>. <source>J. Cheminform.</source>  <year>2011</year>; <volume>3</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brink</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Exner</surname>  <given-names>T.E.</given-names></string-name></person-group>  <article-title>Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2009</year>; <volume>49</volume>:<fpage>1535</fpage>–<lpage>1546</lpage>.<pub-id pub-id-type="pmid">19453150</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayr</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Langer</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Improving small molecule pK</article-title>. <source>Front. Chem.</source>  <year>2022</year>; <volume>10</volume>:<fpage>866585</fpage>.<pub-id pub-id-type="pmid">35721000</pub-id>
</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ropp</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Kaminsky</surname>  <given-names>J.C.</given-names></string-name>, <string-name><surname>Yablonski</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>Dimorphite-DL: an open-source program for enumerating the ionization states of drug-like small molecules</article-title>. <source>J. Cheminform.</source>  <year>2019</year>; <volume>11</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">30767086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>J.Z.H.</given-names></string-name>, <string-name><surname>Ji</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>MolGpka: a web server for small molecule pKa prediction using a graph-convolutional neural network</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2021</year>; <volume>61</volume>:<fpage>3159</fpage>–<lpage>3165</lpage>.<pub-id pub-id-type="pmid">34251213</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riniker</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Landrum</surname>  <given-names>G.A.</given-names></string-name></person-group>  <article-title>Better informed distance geometry: using what we know to improve conformation generation</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>2562</fpage>–<lpage>2574</lpage>.<pub-id pub-id-type="pmid">26575315</pub-id>
</mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buttenschoen</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Morris</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>Deane</surname>  <given-names>C.M.</given-names></string-name></person-group>  <article-title>PoseBusters: aI-based docking methods fail to generate physically valid poses or generalise to novel sequences</article-title>. <source>Chem. Sci.</source>  <year>2024</year>; <volume>15</volume>:<fpage>3130</fpage>–<lpage>3139</lpage>.<pub-id pub-id-type="pmid">38425520</pub-id>
</mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lugari</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Rebuffet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Milhas</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Priet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Roux</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Trinquet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Guillemot</surname>  <given-names>J.C.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins</article-title>. <source>J. Med. Chem.</source>  <year>2016</year>; <volume>59</volume>:<fpage>1634</fpage>–<lpage>1641</lpage>.<pub-id pub-id-type="pmid">26735842</pub-id>
</mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Potlitz</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Link</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Schulig</surname>  <given-names>L.</given-names></string-name></person-group>  <article-title>Advances in the discovery of new chemotypes through ultra-large library docking</article-title>. <source>Expert Opin. Drug Discov.</source>  <year>2023</year>; <volume>18</volume>:<fpage>303</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">36714919</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name>, <string-name><surname>McCammon</surname>  <given-names>J.A.</given-names></string-name></person-group>  <article-title>AutoClickChem: click chemistry in silico</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002397</fpage>.<pub-id pub-id-type="pmid">22438795</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massarotti</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Investigation of the click-chemical space for drug design using ZINClick</article-title>. <source>Methods Mol. Biol.</source>  <year>2021</year>; <volume>2266</volume>:<fpage>3</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33759118</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223810</article-id>
    <article-id pub-id-type="pmid">38686808</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae326</article-id>
    <article-id pub-id-type="publisher-id">gkae326</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemoDOTS: a web server to design chemistry-driven focused libraries</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1906-7128</contrib-id>
        <name>
          <surname>Hoffer</surname>
          <given-names>Laurent</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2806-8675</contrib-id>
        <name>
          <surname>Charifi-Hoareau</surname>
          <given-names>Guillaume</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1084-6312</contrib-id>
        <name>
          <surname>Barelier</surname>
          <given-names>Sarah</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5935-5058</contrib-id>
        <name>
          <surname>Betzi</surname>
          <given-names>Stéphane</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8645-2785</contrib-id>
        <name>
          <surname>Miller</surname>
          <given-names>Thomas</given-names>
        </name>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9877-6058</contrib-id>
        <name>
          <surname>Morelli</surname>
          <given-names>Xavier</given-names>
        </name>
        <!--xavier.morelli@inserm.fr-->
        <xref rid="COR2" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5580-0588</contrib-id>
        <name>
          <surname>Roche</surname>
          <given-names>Philippe</given-names>
        </name>
        <!--philippe.roche@inserm.fr-->
        <xref rid="COR1" ref-type="corresp"/>
        <aff><institution>CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ</institution>, Marseille <addr-line>13273</addr-line>, <country country="FR">France</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +33 486 977 335; Fax: +33 486 977 499; Email: <email>philippe.roche@inserm.fr</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dr Xavier Morelli. Email: <email>xavier.morelli@inserm.fr</email></corresp>
      <fn id="FN1">
        <p>The first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-30">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W461</fpage>
    <lpage>W468</lpage>
    <history>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>11</day>
        <month>3</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae326.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>In drug discovery, the successful optimization of an initial hit compound into a lead molecule requires multiple cycles of chemical modification. Consequently, there is a need to efficiently generate synthesizable chemical libraries to navigate the chemical space surrounding the primary hit. To address this need, we introduce ChemoDOTS, an easy-to-use web server for hit-to-lead chemical optimization freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. With this tool, users enter an activated form of the initial hit molecule then choose from automatically detected reactive functions. The server proposes compatible chemical transformations via an ensemble of encoded chemical reactions widely used in the pharmaceutical industry during hit-to-lead optimization. After selection of the desired reactions, all compatible chemical building blocks are automatically coupled to the initial hit to generate a raw chemical library. Post-processing filters can be applied to extract a subset of compounds with specific physicochemical properties. Finally, explicit stereoisomers and tautomers are computed, and a 3D conformer is generated for each molecule. The resulting virtual library is compatible with most docking software for virtual screening campaigns. ChemoDOTS rapidly generates synthetically feasible, hit-focused, large, diverse chemical libraries with finely-tuned physicochemical properties via a user-friendly interface providing a powerful resource for researchers engaged in hit-to-lead optimization.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae326figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Agence Nationale de la Recherche</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001665</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>ANR-20-CE18-0025</award-id>
        <award-id>ANR-21-CE18-0056</award-id>
        <award-id>ANR-22-CE18-0023</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R37 CA218259</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC2">
    <title>Introduction</title>
    <p>While the identification and validation of hit compounds is a nontrivial first step in the drug discovery process, these compounds normally require subsequent optimization to improve their efficacy, selectivity, and drug-like properties to become chemical probes or therapeutic candidates. During this optimization phase, vast chemical spaces are explored to find analogs or derivatives of the initial hit compounds with improved potency, selectivity, and better pharmacological properties. However, this hit-to-lead (H2L) optimization phase is usually a major bottleneck in drug discovery campaigns (<xref rid="B1" ref-type="bibr">1</xref>). Computational methods are increasingly being integrated into the H2L optimization process to aid in predicting compound properties, optimizing chemical structures, and prioritizing analogs for synthesis (<xref rid="B1" ref-type="bibr">1–5</xref>). One widely established approach to optimize validated hits is known as ‘growing’. This involves expanding chemical structures to introduce new interactions with the target, in order to improve potency and selectivity (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). However, a notable drawback emerges because of this strategy where the molecular weight of the compounds increases, outpacing gains in target affinity or activity, and leading to a phenomenon known as ‘molecular obesity’ (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). Therefore, it is crucial to initiate the H2L optimization phase with so-called ‘ligand-efficient’ molecules exhibiting a low molecular weight and high activity or potency. Such compounds can be obtained through the deconstruction or structural simplification of larger validated hit molecules (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>) or starting with lower molecular weight compounds. Therefore, fragment-based drug discovery (FBDD) appears as one of the most relevant approaches to identify initial hits (<xref rid="B12" ref-type="bibr">12–16</xref>). Fragments are low molecular weight chemical compounds defined by the rule of three (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). One of the key advantages of fragment libraries, compared to standard chemical libraries used in high-throughput screenings, lies in the fact that a small number of fragments can effectively represent a vast chemical space (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In addition, fragments also exhibit high hit rates compared to larger compounds. Because of the small size and low complexity of fragment molecules, FBDD is often combined with structure-based approaches to optimize the initial hits and increase their efficiency and specificity (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). One important aspect of the H2L optimization strategy is considering the synthetic feasibility of the designed compounds. Indeed, each iteration of the growing strategy, aimed at exploring the chemical space around the initial hit, involves synthesizing the designed analogs and testing them experimentally. Achieving this is typically performed through two main strategies. The synthetic feasibility can be estimated using machine learning approaches and expressed through a retrosynthetic score (<xref rid="B23" ref-type="bibr">23</xref>). Alternatively, carefully selected chemical reactions can be employed to virtually design potentially optimized compounds, as demonstrated by the curated collection proposed by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). In this collection, 58 medicinal chemistry-relevant chemical reactions commonly used during the H2L optimization stage in the pharmaceutical industry have been encoded in the machine-readable SMARTS format. These reactions have been implemented in several approaches including DOGS (<xref rid="B25" ref-type="bibr">25</xref>), CROSS (<xref rid="B26" ref-type="bibr">26</xref>), PINGUI/SCUBIDOO (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>), AutoCouple (<xref rid="B29" ref-type="bibr">29</xref>), NAOMINEXT (<xref rid="B30" ref-type="bibr">30</xref>), CHIPMUNK (<xref rid="B31" ref-type="bibr">31</xref>), SwissDrugDesign (<xref rid="B32" ref-type="bibr">32</xref>), AutoGrow4 (<xref rid="B33" ref-type="bibr">33</xref>), OpenChemLib (<xref rid="B34" ref-type="bibr">34</xref>) and eXplore (<xref rid="B35" ref-type="bibr">35</xref>). We also implemented this collection of reactions into our integrated drug design strategy called diversity-oriented target-focused synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). The DOTS approach combines the design of focused chemical libraries and virtual sampling to prioritize the best potential optimizations. Briefly, after hit identification and characterization of its binding mode using structural biophysics method, such as X-ray crystallography, a virtual library is generated. This is achieved by combining an activated core analog of a hit fragment, with a collection of functionalized building blocks (BBs) using the chemical reactions previously defined by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Post-processing stages are then applied to extract a diverse subset of representative compounds that possess reasonable physicochemical properties and are devoid of any undesirable chemical functions. The final library undergoes virtual screening with the S4MPLE tool (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>) to identify the best putative optimizations, aiming to create additional favorable contacts while maintaining the original binding mode. The DOTS approach has been successfully applied to various targets including the zika virus NS5 protein (<xref rid="B39" ref-type="bibr">39</xref>), syntenin PDZ domain protein (<xref rid="B40" ref-type="bibr">40–42</xref>), bromodomain-containing protein 4, BRD4 (<xref rid="B43" ref-type="bibr">43</xref>) and, more recently, a nucleotide kinase, dCK (<xref rid="B44" ref-type="bibr">44</xref>).</p>
    <p>As demonstrated above, the ensemble of chemical reactions defined by Hartenfeller <italic toggle="yes">et al.</italic> is widely used in the chemoinformatics community. However, there is currently no easy-to-use freely accessible web server able to efficiently generate large ready-to-dock virtual libraries using these chemical reactions. In response to this gap, we introduce the ChemoDOTS web server designed to facilitate the generation of focused virtual libraries starting from a user-defined activated fragment. The user first proceeds by uploading or drawing a hit fragment in a sketcher. The web server then automatically identifies the chemical functions that permit the virtual coupling of BBs on the starting molecule. The user then selects one of the identified chemical functions and chooses from a list of compatible chemical reactions. Subsequently, a raw chemical library corresponding to the given reactions and compatible BBs is generated. At this stage, the user is given the option to apply a detailed set of post-processing filters to extract drug-like compounds with specific physicochemical properties. The final stage involves the computation of explicit stereoisomers and tautomers and the generation of a 3D conformer for each compound. A resulting virtual library compatible with most docking software is supplied as mol2 files with atom types and partial charges. The web server is freely accessible to all users, including commercial users, at the following address <ext-link xlink:href="http://chemodots.marseille.inserm.fr/" ext-link-type="uri">http://chemodots.marseille.inserm.fr/</ext-link>.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC3">
    <title>Materials and methods</title>
    <sec id="SEC3-1">
      <title>Web server architecture</title>
      <p>The web server is composed of two parts: the frontend, which handles user interactions, and the backend, which performs the computations. The frontend is a single-page application (SPA) designed with the React framework and embedding the MarvinJS sketcher version 22.11.1 from Chemaxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The backend server is written in Rust to speed up response time. It runs under a virtualized (KVM) Linux instance with a 4 cores/8 hyperthreads Intel CPU, 32 GB of RAM and 90 GB of storage. It makes use of a PostgreSQL database to store all the internal data (e.g. chemical functions, encoded chemical reactions, building blocks) and user-submitted data.</p>
      <p>The raw compound references were stored separately from the building blocks to facilitate the treatment of duplicate molecules within or across providers while maintaining traceability. Chemical reactions, building blocks, and starting fragments were stored in their source/human readable format (SMARTS for reactions, SMILES for building blocks and fragments) to allow extensibility and direct compatibility with external tools. Additionally, they were stored in the RDkit pickle binary format which does not require sanitization and reduces loading time. Each operation was heavily parallelized using a thread pool across all available CPU cores to guarantee maximum performance. This was achieved through Rust's fearless concurrency mechanisms and the Rayon crate for parallel iterators. Database indexes were carefully defined to avoid computational bottlenecks without increasing the database size and reindexing workload for the database management system. To prevent unnecessary calculations, the list of building blocks available for each reaction was precomputed and stored within the database. The combined use of these optimizations allows fast chemical library generation producing at least 50 000 compounds per minute per reaction.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Generation of raw chemical library</title>
      <p>All the chemoinformatics operations are performed using the RDKit framework version 2023.09.5 (<ext-link xlink:href="https://www.rdkit.org/" ext-link-type="uri">https://www.rdkit.org/</ext-link>) unless otherwise stated.</p>
      <sec id="SEC3-2-1">
        <title>Preparation of building blocks</title>
        <p>The list of 626 026 commercially available building blocks as of 2024-02 was retrieved from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) as an SDF file. Then, a standardization pipeline was applied to discard undesirable compounds. First, for each compound, the largest organic fragment was selected discarding salts. The compounds containing only organic atoms (H, C, N, O, P, S), halogens (F, Cl, Br, I) or other atoms relevant in medicinal chemistry (B, Sn) were kept while explicit isotopes were filtered out. A series of filters were then applied to only retrieve BBs with &lt;2 unspecified stereocenters, less than 17 rotatable bonds to limit flexibility, less than 4 rings and between 5 and 24 heavy atoms to restrict the molecules size to an acceptable range. Finally, the compound charges were neutralized. The standardized building blocks were converted into canonical SMILES allowing duplicates to be identified and grouped together with the same internal reference. The resulting chemical structures were serialized using the RDKit pickle format for faster loading from database storage. In the end, 501 542 unique building blocks from MolPort were kept. The same pipeline was applied for the 1 254 866 commercially available building blocks as of 2024-02-05 from the Enamine comprehensive catalog (<ext-link xlink:href="https://enamine.net/building-blocks/building-blocks-catalog" ext-link-type="uri">https://enamine.net/building-blocks/building-blocks-catalog</ext-link>), resulting in the selection of 988 112 unique building blocks.</p>
      </sec>
      <sec id="SEC3-2-2">
        <title>Detection of reactive functions</title>
        <p>Reactive functions are detected by matching each building block against the chemical reactions. A substructure match is performed between an expected reactant template and a building block so that all the reacting building blocks for a given reaction are pre-identified and stored inside the database.</p>
      </sec>
      <sec id="SEC3-2-3">
        <title>List of chemical reactions</title>
        <p>The list of 58 SMART-encoded reactions was taken from the publication of Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). Several in-house reactions (numbered 61–70) used in internal projects have been added to overcome some exceptions in the original list of reactions. The complete list of reactions and their corresponding SMARTS are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>.</p>
      </sec>
      <sec id="SEC3-2-4">
        <title>Detection of compatible chemical reactions</title>
        <p>To identify reactions compatible with a selected chemical function on a provided fragment, the reactant templates from the reaction SMARTS are matched against the fragment to identify the reacting atoms. Only reactions for which one template shares at least one common atom with the function are kept.</p>
      </sec>
      <sec id="SEC3-2-5">
        <title>Generation of raw chemical library</title>
        <p>All fragment atoms not involved in the reaction are masked to prevent reactions with unwanted functions and to speed up the process. Next, the reaction products are generated. Building blocks leading to more than one distinct product are discarded. The products are then grouped by canonical SMILES to identify duplicates (if any) and the 2D coordinates are generated. At this stage, a set of molecular descriptors are computed. These descriptors are the fraction of sp<sup>3</sup> carbons over the total carbon count (Fsp<sup>3</sup>), the number of hydrogen bond donors (HBD), the number of hydrogen bond acceptors (HBA), the logarithm of the predicted partition coefficient between octanol and water (cLogP), the average molecular weight (MW) and the topological polar surface area (TPSA). The products in SMILES/pickle formats and their descriptors are stored inside the database. Finally, the building blocks and products are exported to downloadable SDF and SMILES files.</p>
      </sec>
      <sec id="SEC3-2-6">
        <title>Statistics of raw chemical library</title>
        <p>At each step of the library generation, counters are implemented for individual reactions to report statistics, including the number of reacted building blocks, the number of raw products, the number of duplicates and the number of final unique products. These reaction-specific counters are merged to derive overall statistics for the generated chemical library.</p>
      </sec>
    </sec>
    <sec id="SEC3-3">
      <title>Post-processing stage</title>
      <sec id="SEC3-3-1">
        <title>Filtering using physico-chemical descriptors</title>
        <p>Histograms showing the frequency distribution of compounds are produced using molecular descriptors computed during the raw library generation. For discrete descriptors (HBA, HBD), a single bin is assigned for each unique value within the range of the descriptor. In the case of continuous descriptors (Fsp<sup>3</sup>, cLogP, MW, TPSA) 15 bins are specified. Then, the number of compounds matching a user-defined interval is computed in real time for each descriptor. This involves querying the database using descriptors indexes to retrieve the relevant information.</p>
      </sec>
      <sec id="SEC3-3-2">
        <title>Generation of 2D library</title>
        <p>The available products are collected from the database, then filtered using the intervals defined during the post-processing stage, sorted by molecular weight, and exported to downloadable SMILES and SDF files.</p>
      </sec>
      <sec id="SEC3-3-3">
        <title>Generation of 3D library</title>
        <p>The filtered products are fetched from the database and the major microspecies are computed at pH 7 using a simplified pKa model derived from OpenBabel (<xref rid="B45" ref-type="bibr">45</xref>). The protonation states predicted by OpenBabel are not always reliable. We intend to use other freely available tools in future versions. We are currently investigating different approaches including SPORES (<xref rid="B46" ref-type="bibr">46</xref>) and AI-based tools (<xref rid="B47" ref-type="bibr">47–49</xref>). An embedding step is performed to quickly generate a 3D conformation of the molecule with a correct geometry using ETKDG from RDKit (<xref rid="B50" ref-type="bibr">50</xref>). The validity of the generated conformations can be verified using PoseBusters, a Python package that performs standard quality checks using RDKit (<xref rid="B51" ref-type="bibr">51</xref>). A 3D SDF file is then exported. In addition, the atom types are inferred according to Corina, and Gasteiger partial charges are computed to generate a ready-to-dock mol2 file. It is worth noting that, to reduce computational times, the energy of the generated conformers is currently not minimized using any forcefield. However, we are actively exploring the addition of an optional step for efficient energy minimization to optimize the 3D structure of the generated molecules.</p>
      </sec>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>Program description</title>
    <sec id="SEC4-1">
      <title>Design of the raw focused virtual library</title>
      <p>The overall workflow for designing the raw virtual library can be divided into 4 main steps summarized in Figure <xref rid="F1" ref-type="fig">1</xref>. First, the user must draw or upload the structure of the initial fragment (Figure <xref rid="F1" ref-type="fig">1A</xref>) using the provided Marvin JS sketcher from ChemAxon (<ext-link xlink:href="https://chemaxon.com/" ext-link-type="uri">https://chemaxon.com/</ext-link>). The SMILES code of the user-defined molecule is automatically generated. It is important to note that this reference fragment should contain at least one chemical function compatible with the fragment growing approach. A list of compatible functions is provided via the ‘Reactions’ link on the website, as well as in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> and <xref rid="sup1" ref-type="supplementary-material">S2</xref> and in <xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>. Two examples of molecules are provided to assist the user and can be directly imported into the sketcher (Figure <xref rid="F1" ref-type="fig">1A</xref>). In the next step, chemical functions present in the provided molecule are automatically detected and highlighted in the sketcher upon selection (Figure <xref rid="F1" ref-type="fig">1B</xref>). Users are then prompted to choose the chemical function for the fragment growing approach. For each chemical function, a list of compatible chemical reactions is provided (Figure <xref rid="F1" ref-type="fig">1C</xref>). These chemical reactions are derived in part from the 58 reactions compiled by Hartenfeller <italic toggle="yes">et al.</italic> (<xref rid="B24" ref-type="bibr">24</xref>). The comprehensive list of reactions used in ChemoDOTS, along with their SMARTS representations, is available in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref>–<xref rid="sup1" ref-type="supplementary-material">S5</xref>. These chemical reactions are categorized into three groups based on their relevance. Users are required to select at least one compatible chemical reaction before proceeding to the next step. In the next step, a summary is provided, including the 2D structure of the initial fragment, key molecular descriptors, the SMILES code, the chemical function for fragment growing, and the selected compatible chemical reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the generation of virtual libraries workflow. (<bold>A</bold>) First, the user is prompted to draw or upload the structure of the initial hit fragment into the Marvin JS sketcher. Standard formats such as SMILES, SDF, or PDB are recognized. (<bold>B</bold>) In the second step, all chemical functions compatible with the growing mode are automatically detected. The user should select the desired function for growing. (<bold>C</bold>) All chemical reactions compatible with the chosen chemical function are shown. They are subdivided into three categories depending on their relevance. A text box is provided to search for specific chemical reactions using rule ID numbers or keywords. The different chemical reactions can be highlighted by hovering on the information icons. The user should select at least one chemical reaction before proceeding to the next step. For example, they may choose to perform sulfonamidation, such as the chemical reaction between a primary alkylamine and sulfonyl chlorides (rule 48 defined by Hartenfeller). (<bold>D</bold>) A summary of the selected input is provided along with key molecular descriptors commonly used in early drug discovery. The user should select the building block database that will be used to generate the focused chemical libraries. The raw libraries are generated in seconds to minutes depending on the number of reactions selected and the number of compatible building blocks. In the given example, all selected building blocks contain a sulfonyl chloride function.</p>
        </caption>
        <graphic xlink:href="gkae326fig1" position="float"/>
      </fig>
      <p>In the current version, the database contains 501 542 BBs from MolPort (<ext-link xlink:href="https://www.molport.com/" ext-link-type="uri">https://www.molport.com/</ext-link>) and 988 112 from Enamine (<ext-link xlink:href="https://enamine.net/building-blocks" ext-link-type="uri">https://enamine.net/building-blocks</ext-link>). In future releases, we plan to incorporate collections of BBs from other providers such as ChemDiv (<ext-link xlink:href="https://www.chemdiv.com/catalog/building-blocks" ext-link-type="uri">https://www.chemdiv.com/catalog/building-blocks</ext-link>), ChemSpace (<ext-link xlink:href="https://chem-space.com/building-blocks" ext-link-type="uri">https://chem-space.com/building-blocks</ext-link>) or Otava (<ext-link xlink:href="https://www.otavachemicals.com/products/chemical-building-blocks" ext-link-type="uri">https://www.otavachemicals.com/products/chemical-building-blocks</ext-link>). Additionally, we aim to enable users to upload their own collections of BBs.</p>
      <p>All compounds compatible with the selected parameters are then generated within seconds to minutes depending on the number of BBs that are compatible with the chosen reactions (Figure <xref rid="F1" ref-type="fig">1D</xref>). On average 1000–1500 compounds are generated per second.</p>
    </sec>
    <sec id="SEC4-2">
      <title>Statistics of the raw library</title>
      <p>Upon generating the raw virtual library, a new page is displayed presenting general statistics about the library such as the number of generated compounds and duplicates. For each selected reaction, similar statistics are provided along with its overall contribution to the entire chemical space of the raw library. In addition, a subset of the generated compounds can be displayed in 2D format. At this stage, the raw library and the corresponding BBs can be downloaded in SDF and SMILES formats.</p>
    </sec>
    <sec id="SEC4-3">
      <title>Postprocessing</title>
      <p>The subsequent steps are optional and are highlighted in Figure <xref rid="F2" ref-type="fig">2</xref>. In the post-processing stages, users have the possibility to fine-tune the drug-like properties of the compounds in the virtual library. The distributions of six key molecular descriptors are available encompassing MW, cLogP, HBD, HBA, TPSA, and Fsp<sup>3</sup>. Additional common descriptors will be added in future release or upon request. Users can easily modify the range of each value by using the graphical sliders provided below each plot. The filtered chemical library can then be downloaded in SDF and SMILES formats.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Postprocessing of the raw chemical library. The raw library generated in the initial stage of the process can be refined by adjusting molecular descriptors commonly used in the early phases of drug discovery. These descriptors include molecular weight (MW), logarithm of n-octanol-water partition (cLogP), topological polar surface area (TPSA), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), and fraction of sp<sup>3</sup> carbons (Fsp<sup>3</sup>), an indicator of the three dimensionality of molecules. For each property, the distribution is displayed, and a slider allows users to adjust the minimum and maximum values of each descriptor. The total number of molecules in the filtered library is automatically updated.</p>
        </caption>
        <graphic xlink:href="gkae326fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC4-4">
      <title>Generation of ready-to-dock files</title>
      <p>In the last step, major microspecies, atomic types, partial charges, and one 3D-conformer of each compound in the virtual library are computed. The resulting final 3D library can be downloaded in SDF and ready-to-dock mol2 formats.</p>
    </sec>
    <sec id="SEC4-5">
      <title>Retrospective case study</title>
      <p>We previously engaged in a fragment-based drug design program followed by hit-to-lead optimization to develop chemical probes targeting bromodomain proteins from the BET family (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B52" ref-type="bibr">52</xref>). Bromodomains are protein modules that play a crucial role in gene regulation by recognizing and binding to acetylated lysine residues on histone proteins. The development of bromodomain inhibitors is a promising strategy in cancer treatment offering a targeted approach to modulate gene expression and hinder the growth of cancer cells by disrupting crucial molecular interactions involved in the regulation of gene transcription. Briefly, several primary hits were identified through high throughput screening of an in-house chemical library dedicated to protein–protein interactions (<xref rid="B52" ref-type="bibr">52</xref>). The most potent inhibitor (K<sub>D</sub> ≈ 1.4 μM) was deconstructed, and its affinity was improved using structure–activity relationship (SAR) studies (Figure <xref rid="F3" ref-type="fig">3A</xref>). The resulting fragment was activated with a primary amine to allow growing optimization using our in-house strategy that combines virtual screening with automated real-world synthesis in a platform called Diversity-Oriented Target-focused Synthesis (DOTS, (<xref rid="B36" ref-type="bibr">36</xref>)). This study led to the design of 17 compounds with improved affinities. The affinity of the most potent compound was improved more than 60 times compared to the initial fragment and its binding mode was validated by X-ray crystallography (PDB: 6FO5) (<xref rid="B36" ref-type="bibr">36</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Case study using a retrospective identification of bromodomain inhibitors. (<bold>A</bold>) We previously identified a xanthin derivative inhibitor of bromodomains through high throughput screening (<xref rid="B52" ref-type="bibr">52</xref>). This primary hit (K<sub>D</sub> ≈ 1.4 μM) was deconstructed to find the smallest fragment able to bind the target. This fragment was optimized and activated with a reactive primary amino group (<xref rid="B36" ref-type="bibr">36</xref>). Subsequently, this activated fragment was optimized using our <italic toggle="yes">in-house</italic> hit-to-lead approach called DOTS resulting in 17 compounds with improved affinities including a sub-micromolar probe exhibiting almost a 2-log improvement (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B43" ref-type="bibr">43</xref>). (<bold>B</bold>) To test the ability to generate such compounds, the activated fragment was uploaded in SMILES format on the ChemoDOTS server. The primary alkylamine function was automatically detected as the only reactive function on the molecule. The sulfonamide reaction and the MolPort BBs were then selected to generate the raw virtual library resulting in 5546 sulfonamide derivatives. A post-processing filtering was applied to lead to 3644 compounds which include all 17 optimized compounds identified during the hit-to-lead optimization.</p>
        </caption>
        <graphic xlink:href="gkae326fig3" position="float"/>
      </fig>
      <p>We tested the ability of ChemoDOTS to generate these compounds. The initial fragment activated with a reactive primary amine function was uploaded into the Marvin JS sketcher (Figure <xref rid="F3" ref-type="fig">3B</xref>). As expected, the primary amine function was automatically detected as the only chemical function on the fragment. We then selected the sulfonamidation reaction (#48 from Hartenfeller set of reactions) and the MolPort BBs to generate the raw chemical library. The process resulted in 5546 molecules in 5 s after removal of duplicates. We then applied a standard filtering step using Lipinski-like thresholds (MW &lt; 550 g mol<sup>−1</sup>; log <italic toggle="yes">P</italic> &lt; 5; number of hydrogen bond donors &lt; 5; number of hydrogen bond acceptors &lt; 10) leading to 3644 molecules. All 17 compounds previously identified during the hit-to-lead optimization were present in the final virtual library. All files generated during this retrospective case have been deposited in a zenodo archive (<ext-link xlink:href="https://doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC5">
    <title>Discussion</title>
    <p>In summary, ChemoDOTS is a user-friendly web server that enables the generation and exploration of a vast chemical space around an initial hit molecule by combining molecular building blocks and predefined chemistry rules. Over the last few years, the concept of large chemical space exploration has come to the forefront of drug discovery (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B53" ref-type="bibr">53</xref>). All compounds in the raw virtual library should be easily amenable to organic synthesis in one or two steps. This is achieved by using a collection of robust chemical reactions commonly used in the hit-to-lead optimization phase in the pharmaceutical industry. The drug-like properties of the generated compounds can be improved by adjusting various molecular descriptors. The final chemical library is ready for synthesis or further investigation using either ligand-based or structure-based virtual screening experiments. The high level of parallelization ensures the rapid generation of molecules at more than one thousand molecules generated per second. The global architecture of the server as a database allows efficient web server maintenance and scalability. The current version of ChemoDOTS relies on a collection of more than 500 000 BBs from MolPort and almost a million from Enamine. However, the virtual chemical space covered by ChemoDOTS can be easily extended through the integration of additional BBs from other providers or user-defined sources. Additionally, the incorporation of new chemical reactions including those used in click chemistry offers further avenues for expansion (<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>). The post-processing stage allows users to custom-filter the final collection of compounds by physico-chemical properties in line with the requirements of their drug discovery project. New molecular descriptors can be easily integrated at this stage in future releases of the server. We also anticipate benefiting from users’ feedback to upgrade ChemoDOTS and to deliver a better service. To our knowledge, ChemoDOTS is the only freely accessible functional and maintained web server to combine the design of medchem-compatible focused virtual libraries with an integrated graphical postprocessing analysis. Therefore, it creates a valuable resource for scientists engaged in H2L optimization, particularly for those who may lack the chemoinformatics knowledge required for tasks such as library enumeration, filtering and preparation for subsequent docking experiments.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkae326_Supplemental_File</label>
      <media xlink:href="gkae326_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We express our gratitude to Dr Aznam Yacoub and Namarta Vij from the School of Computer Science (University of Windsor, Canada) for their valuable contribution to the design of the web server's frontend. Special thanks go to Dr Samuel Granjeaud for his help and guidance in web developments. Our appreciation extends to Drs Sébastien Abel, Paul Brémond and Sébastien Combes for their insightful discussions about the chemical reactions used in ChemoDOTS. We would also like to thank Drs Dominique Douguet and Magali Saez Ayala for testing the web server. Lastly, we extend our thanks to the DISC platform for providing the facilities to host the ChemoDOTS web server.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC6">
    <title>Data availability</title>
    <p>The ChemoDOTS web server is freely available at <ext-link xlink:href="https://chemodots.marseille.inserm.fr/" ext-link-type="uri">https://chemodots.marseille.inserm.fr/</ext-link>. All scripts used in ChemoDOTS backend have been deposited on GitHub (<ext-link xlink:href="https://github.com/iSCBTeam/ChemoDOTS" ext-link-type="uri">https://github.com/iSCBTeam/ChemoDOTS</ext-link>). Permanent DOI of the code used for ChemoDOTS: Backend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585089" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585089</ext-link> Frontend: <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25585092" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25585092</ext-link> The list of chemical functions, the list of reactions, and the final BBs from MolPort and Enamine (in SMILES format) are available via Zenodo repository at <ext-link xlink:href="https://doi.org/10.5281/zenodo.10776787" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10776787</ext-link>. Files from the retrospective test case can be accessed through the Zenodo repository at <ext-link xlink:href="https://dx.doi.org/10.5281/zenodo.10701800" ext-link-type="uri">https://dx.doi.org/10.5281/zenodo.10701800</ext-link>.</p>
  </sec>
  <sec id="SEC7">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkae326#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC8">
    <title>Funding</title>
    <p>Agence Nationale de la Recherche [ANR-20-CE18-0025, ANR-21-CE18-0056, ANR-22-CE18-0023]; National Cancer Institute [R37 CA218259 to T.W.M.]; G.C. is funded by ANR-22-CE18-0023. Funding for open access charge: Agence Nationale de la Recherche [ANR-21-CE18-0056].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Laurent Hoffer, Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.</p>
  </notes>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name></person-group>  <article-title>Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches</article-title>. <source>Mol. Inform.</source>  <year>2018</year>; <volume>37</volume>:<fpage>e1800059</fpage>.<pub-id pub-id-type="pmid">30051601</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frye</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bhat</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Akinsanya</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>From computer-aided drug discovery to computer-driven drug discovery</article-title>. <source>Drug Discov. Today Technol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>111</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">34906321</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Souza Neto</surname>  <given-names>L.R.</given-names></string-name>, <string-name><surname>Moreira-Filho</surname>  <given-names>J.T.</given-names></string-name>, <string-name><surname>Neves</surname>  <given-names>B.J.</given-names></string-name>, <string-name><surname>Maidana</surname>  <given-names>R.L.B.R.</given-names></string-name>, <string-name><surname>Guimarães</surname>  <given-names>A.C.R.</given-names></string-name>, <string-name><surname>Furnham</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Andrade</surname>  <given-names>C.H.</given-names></string-name>, <string-name><surname>Silva</surname>  <given-names>F.P.</given-names></string-name></person-group>  <article-title>Strategies to support fragment-to-lead optimization in drug discovery</article-title>. <source>Front. Chem.</source>  <year>2020</year>; <volume>8</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">32133344</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Talevi</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Computer-aided drug discovery and design: recent advances and future prospects</article-title>. <source>Methods Mol. Biol.</source>  <year>2024</year>; <volume>2714</volume>:<fpage>1</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">37676590</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moret</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Clark</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Hafner</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Lounkine</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Medvedovic</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Jenkins</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sorger</surname>  <given-names>P.K.</given-names></string-name></person-group>  <article-title>Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries</article-title>. <source>Cell Chem. Biol.</source>  <year>2019</year>; <volume>26</volume>:<fpage>765</fpage>–<lpage>777</lpage>.<pub-id pub-id-type="pmid">30956147</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirsch</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hartman</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Hirsch</surname>  <given-names>A.K.H.</given-names></string-name>, <string-name><surname>Empting</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>Concepts and core principles of fragment-based drug design</article-title>. <source>Molecules</source>. <year>2019</year>; <volume>24</volume>:<fpage>4309</fpage>.<pub-id pub-id-type="pmid">31779114</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bienstock</surname>  <given-names>R.J.</given-names></string-name></person-group>  <article-title>Computational methods for fragment-based ligand design: growing and linking</article-title>. <source>Methods Mol. Biol.</source>  <year>2015</year>; <volume>1289</volume>:<fpage>119</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">25709037</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Polanski</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Bogocz</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Tkocz</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>The analysis of the market success of FDA approvals by probing top 100 bestselling drugs</article-title>. <source>J. Comput. Aided Mol. Des.</source>  <year>2016</year>; <volume>30</volume>:<fpage>381</fpage>–<lpage>389</lpage>.<pub-id pub-id-type="pmid">27125384</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hann</surname>  <given-names>M.M.</given-names></string-name></person-group>  <article-title>Molecular obesity, potency and other addictions in drug discovery</article-title>. <source>Med.Chem. Commun.</source>  <year>2011</year>; <volume>2</volume>:<fpage>349</fpage>–<lpage>355</lpage>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fry</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Wartchow</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Graves</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Janson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lukacs</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Kammlott</surname>  <given-names>U.</given-names></string-name>, <string-name><surname>Belunis</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Palme</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vu</surname>  <given-names>B.</given-names></string-name></person-group>  <article-title>Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2013</year>; <volume>4</volume>:<fpage>660</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">24900726</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Dong</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Sheng</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Structural simplification: an efficient strategy in lead optimization</article-title>. <source>Acta Pharm Sin B</source>. <year>2019</year>; <volume>9</volume>:<fpage>880</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">31649841</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferreira</surname>  <given-names>L.G.</given-names></string-name>, <string-name><surname>Andricopulo</surname>  <given-names>A.D.</given-names></string-name></person-group>  <article-title>From protein structure to small-molecules: recent advances and applications to fragment-based drug discovery</article-title>. <source>Curr. Top. Med. Chem.</source>  <year>2017</year>; <volume>17</volume>:<fpage>2260</fpage>–<lpage>2270</lpage>.<pub-id pub-id-type="pmid">28240184</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romasanta</surname>  <given-names>A.K.S.</given-names></string-name>, <string-name><surname>van der Sijde</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Hellsten</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Keseru</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>van Muijlwijk-Koezen</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name></person-group>  <article-title>When fragments link: a bibliometric perspective on the development of fragment-based drug discovery</article-title>. <source>Drug Discov. Today</source>. <year>2018</year>; <volume>23</volume>:<fpage>1596</fpage>–<lpage>1609</lpage>.<pub-id pub-id-type="pmid">29738823</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walsh</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>de Esch</surname>  <given-names>I.J.P.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Woodhead</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Wren</surname>  <given-names>E.</given-names></string-name></person-group>  <article-title>Fragment-to-lead medicinal chemistry publications in 2021</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>1137</fpage>–<lpage>1156</lpage>.<pub-id pub-id-type="pmid">36622056</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name>, <string-name><surname>Fesik</surname>  <given-names>S.W.</given-names></string-name>, <string-name><surname>Hubbard</surname>  <given-names>R.E.</given-names></string-name>, <string-name><surname>Jahnke</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>Twenty years on: the impact of fragments on drug discovery</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2016</year>; <volume>15</volume>:<fpage>605</fpage>–<lpage>619</lpage>.<pub-id pub-id-type="pmid">27417849</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Introduction to fragment-based drug discovery</article-title>. <source>Top. Curr. Chem.</source>  <year>2012</year>; <volume>317</volume>:<fpage>1</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">21695633</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Congreve</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Carr</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>A ‘rule of three’ for fragment-based lead discovery?</article-title>. <source>Drug Discov. Today</source>. <year>2003</year>; <volume>8</volume>:<fpage>876</fpage>–<lpage>877</lpage>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jhoti</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Williams</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Rees</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Murray</surname>  <given-names>C.W.</given-names></string-name></person-group>  <article-title>The ‘rule of three’ for fragment-based drug discovery: where are we now?</article-title>. <source>Nat. Rev. Drug Discov.</source>  <year>2013</year>; <volume>12</volume>:<fpage>644</fpage>–<lpage>645</lpage>.<pub-id pub-id-type="pmid">23845999</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Renaud</surname>  <given-names>J.P.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>Fragment-based drug design: computational &amp; experimental state of the art</article-title>. <source>Comb. Chem. High Throughput Screen.</source>  <year>2011</year>; <volume>14</volume>:<fpage>500</fpage>–<lpage>520</lpage>.<pub-id pub-id-type="pmid">21521152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname>  <given-names>D.E.</given-names></string-name>, <string-name><surname>Coyne</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Hudson</surname>  <given-names>S.A.</given-names></string-name>, <string-name><surname>Abell</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Fragment-based approaches in drug discovery and chemical biology</article-title>. <source>Biochemistry</source>. <year>2012</year>; <volume>51</volume>:<fpage>4990</fpage>–<lpage>5003</lpage>.<pub-id pub-id-type="pmid">22697260</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Montfort</surname>  <given-names>R.L.M.</given-names></string-name>, <string-name><surname>Workman</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Structure-based drug design: aiming for a perfect fit</article-title>. <source>Essays Biochem.</source>  <year>2017</year>; <volume>61</volume>:<fpage>431</fpage>–<lpage>437</lpage>.<pub-id pub-id-type="pmid">29118091</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>Z.Z.</given-names></string-name>, <string-name><surname>Shi</surname>  <given-names>X.X.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>G.Y.</given-names></string-name>, <string-name><surname>Hao</surname>  <given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>G.F.</given-names></string-name></person-group>  <article-title>Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions</article-title>. <source>Trends Biochem. Sci.</source>  <year>2023</year>; <volume>48</volume>:<fpage>539</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">36841635</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>W.Y.</given-names></string-name></person-group>  <article-title>DFRscore: deep learning-based scoring of synthetic complexity with drug-focused retrosynthetic analysis for high-throughput virtual screening</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2023</year>; <volume>64</volume>:<fpage>2432</fpage>–<lpage>2444</lpage>.<pub-id pub-id-type="pmid">37651152</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Eberle</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Meier</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Nieto-Oberhuber</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Altmann</surname>  <given-names>K.H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Jacoby</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Renner</surname>  <given-names>S.</given-names></string-name></person-group>  <article-title>A collection of robust organic synthesis reactions for in silico molecule design</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2011</year>; <volume>51</volume>:<fpage>3093</fpage>–<lpage>3098</lpage>.<pub-id pub-id-type="pmid">22077721</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartenfeller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Zettl</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Walter</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Rupp</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Reisen</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Proschak</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Weggen</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Stark</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Schneider</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>DOGS: reaction-driven de novo design of bioactive compounds</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002380</fpage>.<pub-id pub-id-type="pmid">22359493</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evers</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hessler</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>L.H.</given-names></string-name>, <string-name><surname>Werrel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Monecke</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Matter</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents</article-title>. <source>J. Med. Chem.</source>  <year>2013</year>; <volume>56</volume>:<fpage>4656</fpage>–<lpage>4670</lpage>.<pub-id pub-id-type="pmid">23627295</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic rractability</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>1824</fpage>–<lpage>1835</lpage>.<pub-id pub-id-type="pmid">26282054</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chevillard</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rimmer</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Betti</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Pardon</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Ballet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>van Hilten</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Steyaert</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Diederich</surname>  <given-names>W.E.</given-names></string-name>, <string-name><surname>Kolb</surname>  <given-names>P.</given-names></string-name></person-group>  <article-title>Binding-site compatible fragment growing applied to the design of β2-adrenergic receptor ligands</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>1118</fpage>–<lpage>1129</lpage>.<pub-id pub-id-type="pmid">29364664</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Batiste</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Unzue</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Dolbois</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hassler</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Deerain</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Zhu</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Spiliotopoulos</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Nevado</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Caflisch</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Chemical space expansion of bromodomain ligands guided by in silico virtual couplings (AutoCouple)</article-title>. <source>ACS Cent. Sci.</source>  <year>2018</year>; <volume>4</volume>:<fpage>180</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">29532017</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sommer</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Flachsenberg</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Rarey</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>NAOMInext - synthetically feasible fragment growing in a structure-based design context</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>163</volume>:<fpage>747</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">30576905</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humbeck</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Weigang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Schäfer</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Mutzel</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Koch</surname>  <given-names>O.</given-names></string-name></person-group>  <article-title>CHIPMUNK: a virtual synthesizable small-molecule library for medicinal chemistry, exploitable for protein-protein interaction modulators</article-title>. <source>ChemMedChem</source>. <year>2018</year>; <volume>13</volume>:<fpage>532</fpage>–<lpage>539</lpage>.<pub-id pub-id-type="pmid">29392860</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daina</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Zoete</surname>  <given-names>V.</given-names></string-name></person-group>  <article-title>Application of the SwissDrugDesign online resources in virtual screening</article-title>. <source>Int. J. Mol. Sci.</source>  <year>2019</year>; <volume>20</volume>:<fpage>4612</fpage>.<pub-id pub-id-type="pmid">31540350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spiegel</surname>  <given-names>J.O.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title>. <source>J. Cheminform.</source>  <year>2020</year>; <volume>12</volume>:<fpage>25</fpage>.<pub-id pub-id-type="pmid">33431021</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wahl</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Sander</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Fully automated creation of virtual chemical fragment spaces using the open-source library OpenChemLib</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2022</year>; <volume>62</volume>:<fpage>2202</fpage>–<lpage>2211</lpage>.<pub-id pub-id-type="pmid">35073086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neumann</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Marrison</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Klein</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>Relevance of the trillion-sized chemical space “eXplore” as a source for drug discovery</article-title>. <source>ACS Med. Chem. Lett.</source>  <year>2023</year>; <volume>14</volume>:<fpage>466</fpage>–<lpage>472</lpage>.<pub-id pub-id-type="pmid">37077402</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.V.</given-names></string-name>, <string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Muller</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Fedorov</surname>  <given-names>A.Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Amouric</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach</article-title>. <source>J. Med. Chem.</source>  <year>2018</year>; <volume>61</volume>:<fpage>5719</fpage>–<lpage>5732</lpage>.<pub-id pub-id-type="pmid">29883107</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Chira</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Marcou</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Varnek</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE – Sampler for Multiple Protein-Ligand Entities: methodology and rigid-site docking benchmarking</article-title>. <source>Molecules</source>. <year>2015</year>; <volume>20</volume>:<fpage>8997</fpage>–<lpage>9028</lpage>.<pub-id pub-id-type="pmid">25996209</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Horvath</surname>  <given-names>D</given-names></string-name></person-group>  <article-title>S4MPLE–sampler for multiple protein-ligand entities: simultaneous docking of several entities</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2013</year>; <volume>53</volume>:<fpage>88</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">23215156</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hernandez</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Coutard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Querat</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Decroly</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2019</year>; <volume>161</volume>:<fpage>323</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">30368131</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kashyap</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Kovalskyy</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ghossoub</surname>  <given-names>R.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loadifing with syndecan and EpCAM cargo</article-title>. <source>J. Extracell. Vesicles</source>. <year>2020</year>; <volume>10</volume>:<fpage>e12039</fpage>.<pub-id pub-id-type="pmid">33343836</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Benmansour</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Egea-Jimenez</surname>  <given-names>A.L.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Morelli</surname>  <given-names>X.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread</article-title>. <source>Eur. J. Med. Chem.</source>  <year>2021</year>; <volume>223</volume>:<fpage>113601</fpage>.<pub-id pub-id-type="pmid">34153575</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Garcia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Leblanc</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Feracci</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Betzi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Daulat</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Zimmermann</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Barral</surname>  <given-names>K.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Discovery of a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein interaction: a semi-automated “hit identification-to-optimization” approach</article-title>. <source>J. Med. Chem.</source>  <year>2023</year>; <volume>66</volume>:<fpage>4633</fpage>–<lpage>4658</lpage>.<pub-id pub-id-type="pmid">36939673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrasco</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Montersino</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Restouin</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Castellano</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Casassa</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Roche</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Pasquier</surname>  <given-names>E.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>CRCM5484: a BET-BDII selective compound with differential anti-leukemic drug modulation</article-title>. <source>J. Med. Chem.</source>  <year>2022</year>; <volume>65</volume>:<fpage>5660</fpage>–<lpage>5674</lpage>.<pub-id pub-id-type="pmid">35348328</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saez-Ayala</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Hoffer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Abel</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ben Yaala</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Sicard</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Andrieu</surname>  <given-names>G.P.</given-names></string-name>, <string-name><surname>Latiri</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Davison</surname>  <given-names>E.K.</given-names></string-name>, <string-name><surname>Ciufolini</surname>  <given-names>M.A.</given-names></string-name>, <string-name><surname>Brémond</surname>  <given-names>P.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia</article-title>. <source>Nat. Commun.</source>  <year>2023</year>; <volume>14</volume>:<fpage>3079</fpage>.<pub-id pub-id-type="pmid">37248212</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Boyle</surname>  <given-names>N.M.</given-names></string-name>, <string-name><surname>Banck</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>James</surname>  <given-names>C.A.</given-names></string-name>, <string-name><surname>Morley</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vandermeersch</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Hutchison</surname>  <given-names>G.R.</given-names></string-name></person-group>  <article-title>Open Babel: an open chemical toolbox</article-title>. <source>J. Cheminform.</source>  <year>2011</year>; <volume>3</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brink</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Exner</surname>  <given-names>T.E.</given-names></string-name></person-group>  <article-title>Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2009</year>; <volume>49</volume>:<fpage>1535</fpage>–<lpage>1546</lpage>.<pub-id pub-id-type="pmid">19453150</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayr</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Wieder</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Langer</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Improving small molecule pK</article-title>. <source>Front. Chem.</source>  <year>2022</year>; <volume>10</volume>:<fpage>866585</fpage>.<pub-id pub-id-type="pmid">35721000</pub-id>
</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ropp</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Kaminsky</surname>  <given-names>J.C.</given-names></string-name>, <string-name><surname>Yablonski</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name></person-group>  <article-title>Dimorphite-DL: an open-source program for enumerating the ionization states of drug-like small molecules</article-title>. <source>J. Cheminform.</source>  <year>2019</year>; <volume>11</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">30767086</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>J.Z.H.</given-names></string-name>, <string-name><surname>Ji</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>MolGpka: a web server for small molecule pKa prediction using a graph-convolutional neural network</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2021</year>; <volume>61</volume>:<fpage>3159</fpage>–<lpage>3165</lpage>.<pub-id pub-id-type="pmid">34251213</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riniker</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Landrum</surname>  <given-names>G.A.</given-names></string-name></person-group>  <article-title>Better informed distance geometry: using what we know to improve conformation generation</article-title>. <source>J. Chem. Inf. Model.</source>  <year>2015</year>; <volume>55</volume>:<fpage>2562</fpage>–<lpage>2574</lpage>.<pub-id pub-id-type="pmid">26575315</pub-id>
</mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buttenschoen</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Morris</surname>  <given-names>G.M.</given-names></string-name>, <string-name><surname>Deane</surname>  <given-names>C.M.</given-names></string-name></person-group>  <article-title>PoseBusters: aI-based docking methods fail to generate physically valid poses or generalise to novel sequences</article-title>. <source>Chem. Sci.</source>  <year>2024</year>; <volume>15</volume>:<fpage>3130</fpage>–<lpage>3139</lpage>.<pub-id pub-id-type="pmid">38425520</pub-id>
</mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raux</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Voitovich</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Derviaux</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lugari</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Rebuffet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Milhas</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Priet</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Roux</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Trinquet</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Guillemot</surname>  <given-names>J.C.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins</article-title>. <source>J. Med. Chem.</source>  <year>2016</year>; <volume>59</volume>:<fpage>1634</fpage>–<lpage>1641</lpage>.<pub-id pub-id-type="pmid">26735842</pub-id>
</mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Potlitz</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Link</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Schulig</surname>  <given-names>L.</given-names></string-name></person-group>  <article-title>Advances in the discovery of new chemotypes through ultra-large library docking</article-title>. <source>Expert Opin. Drug Discov.</source>  <year>2023</year>; <volume>18</volume>:<fpage>303</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">36714919</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durrant</surname>  <given-names>J.D.</given-names></string-name>, <string-name><surname>McCammon</surname>  <given-names>J.A.</given-names></string-name></person-group>  <article-title>AutoClickChem: click chemistry in silico</article-title>. <source>PLoS Comput. Biol.</source>  <year>2012</year>; <volume>8</volume>:<fpage>e1002397</fpage>.<pub-id pub-id-type="pmid">22438795</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massarotti</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Investigation of the click-chemical space for drug design using ZINClick</article-title>. <source>Methods Mol. Biol.</source>  <year>2021</year>; <volume>2266</volume>:<fpage>3</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33759118</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
